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ADP-RIBOSYLATION FACTOR 6 (ARF6) REGULATES INTEGRIN αIIbβ3 TRAFFICKING, 
PLATELET SPREADING, AND CLOT RETRACTION 
 
Endocytic trafficking of platelet surface receptors plays a role in the accumulation of 
granule cargo (i.e. fibrinogen and VEGF) and thus could contribute to hemostasis, 
angiogenesis, or inflammation. However, the mechanisms of platelet endocytosis are 
poorly understood. The small GTP-binding protein, ADP-ribosylation factor 6 (Arf6), 
regulates integrin trafficking in nucleated cells; therefore, we posited that Arf6 functions 
similarly in platelets. To address this, we generated platelet-specific, Arf6 knockout mice. 
Arf6-/- platelets had a storage defect for fibrinogen but not other cargo, implying Arf6’s 
role in integrin αIIbβ3 trafficking. Additionally, platelets from Arf6-/- mice injected with 
biotinylated-fibrinogen, showed lower accumulation of the modified protein than did WT 
mice. Resting and activated αIIbβ3 levels, measured by FACS, were unchanged in Arf6-/- 
platelets. Arf6-/- platelets had normal agonist-induced aggregation and ATP release; 
however, they showed faster clot retraction and enhanced spreading, which appears due 
to altered αIIbβ3 trafficking since myosin light chain phosphorylation and Rac1 activation, 
in response to thrombin, were unaffected. Arf6-/- mice showed no hemostasis defect in 
tail-bleeding or FeCl3–induced carotid injury assays. These data suggest a role for Arf6 in 
integrin αIIbβ3 trafficking in platelets.  
Additionally, the regulation of Arf6 in platelets was also investigated, focusing on integrin 
αIIbβ3 outside-in signaling which was suggested to be responsible for the second wave of 
Arf6-GTP loss. G protein-coupled receptor kinase-interacting protein 1 (GIT1), a GTPase-
activating protein (GAP) toward Arf6, is suggested to be involved in αIIbβ3 downstream 
signaling. I found that GIT1, complex with β-PIX, was translocated to the detergent-
insoluble pellet upon human platelet activation, a process that is blocked by RGDS and 
myrArf6 peptide treatment. Moreover, tyrosine-phosphorylation of GIT1 was impaired by 
treatment with both peptides or with actin polymerization inhibitors. GIT1’s role in 
 
 
platelets was further studied using platelet-specific, GIT1 knockout mice. GIT1-/- platelets 
failed to show any defect, including clot retraction or fibrinogen storage. Unlike human 
platelets, GIT1 expression levels were much lower in mouse platelets, suggesting that 
GIT2 may be the functionally relevant Arf6-GAP in mouse platelets. The data in this 
dissertation identify that Arf6 mediates fibrinogen storage, implying its role in integrin 
αIIbβ3 trafficking in platelets.  
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Chapter One: Introduction 
Subsection One: Platelets and Their Roles 
Platelet Biology Overview 
Platelets are anuclear cytoplasmic fragments released in bone marrow from their 
precursor cells, megakaryocytes [1, 2]. They are the smallest blood cells in the blood 
stream and are important players for thrombosis and hemostasis [3, 4]. Platelets have 
several featured characteristics to fulfil their functions. First, platelets express a 
unique set of receptors on their surface, including P2Y purinergic receptors, PAR 
(protease activated receptor) receptors, GPVI (glycoprotein VI), and integrins, which 
are adhesion molecules linking the intracellular actin cytoskeleton network to the 
extracellular matrix. These receptors, upon stimulation by their ligands, induce 
different degrees of platelet activation in a spatiotemporally coordinated manner [5]. 
This is essential for the regulation of platelet activity. Additionally, endocytic 
trafficking of these receptors is an important mechanism for platelets to communicate 
with the surrounding environment by taking up or releasing small molecules and 
proteins, or by changing the surface level of these receptors at the plasma membrane 
[6-11]. Secondly, platelets contain three main types of granules, α-granule, dense 
granule and lysosome [12, 13]. Upon platelet activation, granule content is released 
by fusion of granule membranes to the plasma membrane. This fusion is mediated by 
SNAREs (soluble N-ethylmaleimide-sensitive fusion protein attachment receptor) 
proteins. The released material (releasate) from the three granules can either affect 
platelet activity in an autocrine or paracrine manner or affect other cells in the 
surrounding microenvironment. Lastly, human and mouse platelets have a unique 
membrane structure, the open canalicular system (OCS) which is thought to be a 
membrane reservoir that is important for platelet spreading on a wounded site [14, 
15]. Therefore, platelets are unique cells, whose activity is highly regulated and whose 
function actually has been explored extensively beyond thrombosis and hemostasis. 
Platelet Structures 
Platelets are produced from megakaryocytes in bone marrow. Their production is a 
tightly regulated process, involving a complex of transcription factors, signaling 
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molecules and microenvironment [16, 17]. Each day, about 1 X 1011 platelets are 
produced in a healthy adult to maintain a normal platelet count in the body. Once 
released from megakaryocytes, platelets have a lifespan of approximately 10 days [18].  
Resting platelets are of discoid shape, which is maintained by both microtubule and 
filamentous-actin cytoskeletons [19-21]. They contain three major granules, dense 
granule, α-granule, and lysosome [12]. In addition to these three major granules, 
platelets also contain mitochondria, peroxisomes, a dense-tubular system [22], and 
multivesicular bodies (MVBs) which are suggested to be an intermediate stage in α-
granule and dense-granule biogenesis [23]. There are approximately three to eight 
dense granules per platelet [24]. These granules contain small molecules such as 
calcium, serotonin, ADP, and ATP, etc. ADP is important for amplification of platelet 
activation during thrombosis. Each platelet has about fifty to eighty α-granules [25]. 
These granules house various biologically active proteins, which are involved in a vast 
array of physiological processes, including adhesion, angiogenesis and inflammation. 
α-Granule cargo are from two major sources. One is derived endogenously by protein 
synthesis in the megakaryocyte, e.g. β-thromboglobulin [26], platelet factor 4 (PF4) 
[27], and von Willebrand Factor (vWF) [28]. The other is taken up from plasma via 
receptor-mediated endocytosis, fluid phase pinocytosis or perhaps even phagocytosis. 
As an example, fibrinogen uptake is dependent on the major membrane glycoprotein 
IIbIIIa (integrin αIIbβ3) [29]. Alpha granules also contain a number of membrane 
proteins essential for platelet functions, including integrin αIIbβ3, P-selectin (CD62P) 
and CD36 [25]. Upon granule exocytosis, following platelet activation, α-granules not 
only release their contents but also become part of the plasma membrane thus 
facilitating the exposure of the granule membrane proteins on the plasma membrane. 
Lysosomes are another type of organelle/granule in platelets, which contain 
degradative enzymes, including β-hexosaminidase, cathepsin, and acid phosphatases 
[30]. These enzymes are also released upon platelet activation, but only in response 
to strong agonists [31]. Activation-dependent granule secretion is mediated by two 
sets of SNARE proteins, vesicle SNAREs (v-SNAREs) and target membrane SNAREs (t-
SNAREs) [32, 33]. Using genetic animal model and platelets from patient with 
secretion defects, it has been demonstrated that VAMP8 (vesicle-associated 
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membrane protein 8, v-SNARE) [34], Syntaxin11 (t-SNARE) [13], and SNAP23 (t-SNARE) 
[35] are the major SNARE proteins critical for platelet exocytosis.  
Another unique but obvious structure in platelets is the open canalicular system (OCS) 
[15]. The OCS is characterized by the invagination of the plasma membrane. It was 
thought to have three major functions [14, 36]. The first one is as a membrane 
reservoir which is important for the formation of filopodia and for spreading following 
platelet adhesion to an activating surface. Second is to be a route through which 
external elements could enter into platelets or granule cargo could release to platelet 
exterior. It is thought that the OCS is one of the places where fibrinogen could be 
bound before being internalized in an integrin αIIbβ3-dependent manner [37]. Lastly, 
the OCS could be used as a cryptic store of plasma membrane glycoproteins [38]; 
although exposure of many of these proteins is now thought to occur subsequent to 
granule fusion. Recent unpublished data from the Storrie group has suggested that 
the OCS may be more complex. Tomography analysis of platelets has suggested that 
the OCS may, in fact, represent endosomal compartments that are not connected to 
the plasma membrane but that fuse to the plasma membrane at the earliest stages of 
platelet activation. These new findings greatly affect previous visions of the OCS and 
suggest that platelets may contain a much more extensive endosomal membrane 
system than previously thought. This interpretation is supported by data presented in 
this thesis. 
Platelet Receptors and Their Signaling during Platelet Activation 
Platelets express many receptors on their plasma membrane. The number of the 
receptors is still increasing due to recent proteomic analyses [39]. Here, only the 
receptors related to this thesis work are discussed. Interactions between the ligands 
and their corresponding receptors induce different downstream signaling pathways 
which are essential for platelet activation, e.g. adhesion, aggregation, spreading, and 
clot retraction [5]. In vivo, these receptors are working cooperatively rather than 
independently in order for platelets to do what they are needed to do.  
G protein-coupled receptors 
Platelets express multiple G protein-coupled receptors (GPCRs), a family of seven-
transmembrane domain receptors that bind to and transmit signals through 
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heterotrimeric G proteins [40]. The heterotrimeric G proteins consist of three subunits, 
α, β, and γ. Upon ligand binding to the receptor, the α subunit (Gα) is activated, 
converting from the inactive GDP-bound form to the active GTP-bound form, and is 
dissociated from the receptor and the Gβγ complex. By interacting with their own 
specific downstream targets, Gα and Gβγ transmit the receptor’s signals [41]. Based 
on functional specificity, Gα subunit can be classified into Gq, G12/G13, Gi and Gs 
subfamilies. The GPCRs expressed on platelet surface include protease-activated 
receptors (PARs), purinergic receptors (P2Y receptors), and thromboxane A2 (TXA2) 
receptor (TP).  
There are four PAR receptors, PAR1 – PAR4 [42]. Human platelets express PAR1 and 
PAR4, while mouse platelets express PAR3 and PAR4. These receptors are activated 
by thrombin, one of the most potent platelet agonists. PAR1 and PAR4 in human 
platelets are activated by low and high concentrations of thrombin, respectively [43]. 
In contrast, PAR3 in mouse platelets functions as a co-receptor for PAR4 [44]. These 
PARs are coupled to Gq- and G12/G13-mediated signaling transductions. Since thrombin 
is generated on a cellular surface when the subendothelial Tissue Factor is exposed to 
plasma coagulation factors [45], PARs-mediated platelet activation occurs after 
platelet adhesion and some level of platelet activation. During the thrombus 
formation, thrombin is further generated and released [46]. Thus, thrombin-mediated 
platelet activation acts in a positive-feedback manner to greatly amplify platelet 
activation and to recruit more platelets to the growing thrombus. This positive-
feedback mechanism is also shared by other GPCRs-mediated platelets activation as 
discussed below. 
Platelets contain two major purinergic receptors, P2Y1 and P2Y12 [47-51]. Activation of 
these receptors is mediated by adenosine diphosphate (ADP) which is stored at high 
concentrations in dense granules in platelets and is released upon platelet activation. 
Released ADP activates platelets in either an autocrine manner or a paracrine manner. 
P2Y1 and P2Y12 are coupled to Gq and Gi, respectively. Like thrombin, ADP is important 
to amplify platelet activation and to recruit more platelets to the growing thrombus. 
Moreover, P2Y receptors have a unique feature – endocytic trafficking [52]. Endocytic 
trafficking of P2Y receptors allows platelets to be desensitized and resensitized to ADP. 
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It has been shown that P2Y1 and P2Y12, upon ADP stimulation, rapidly desensitize in a 
kinase-dependent manner [53]. Endocytosis of P2Y1 is dependent on protein kinase C 
(PKC) activity, whereas P2Y12 requires G protein-coupled receptor kinase (GSK). After 
removal of agonist, P2Y receptors recycle back to the cell surface, a process that is 
called resensitization. ADP-ribosylation factor 6 (Arf6) has been suggested to be 
important for P2Y12 internalization by regulating Nm23-H1, an NDP (nucleoside 
diphosphate) kinase which facilitates dynamin-dependent fission of clathrin-coated 
vesicles [54]. However, it is still unclear what physiological significance this 
desensitization and resensitization cycling of P2Y receptors has. 
Thromboxane A2 is another soluble agonist that mediates the amplification of platelet 
activation and recruitment [5]. It is generated from arachidonic acid by 
cyclooxygenase-1 [41], and is released by activated platelets, though the mechanism 
of this release is unknown. TxA2 receptor (TP) is coupled to Gq and G12/G13 [55, 56]. 
Mice lacking TP have prolonged bleeding times and are unable to form stable thrombi 
[57]. Both ADP and TxA2 are thought to be weaker agonists that which serve to 
enhance thrombosis but are generally not sufficient to initiate thrombosis unless 
present in high local concentrations. 
GPIb-IX-V complex (GPIb complex) 
GPIb complex is a transmembrane receptor, almost exclusively expressed on platelets 
[58]. The interactions of GPIb complex with von Willebrand factor (vWF) are crucial 
for the initial capture (transient adhesion) of circulating platelets to the exposed 
subendothelial matrix [59, 60]. VWF deposited on the subendothelial matrix is either 
synthesized by endothelial cells or recruited by collagen fiber from plasma [28]. 
Binding of GPIb complex to vWF activates downstream signaling cascade, leading to 
integrin activation (see below) and integrin-dependent stable platelet adhesion and 
aggregation [61-66]. GPIb complex also functions to be a binding site for thrombin, 
allowing platelet activation by low concentrations of thrombin [67]. 
Glycoprotein VI (GPVI) 
GPVI is a member of the immunoglobulin (lg)-like receptors and is one of the collagen 
receptors expressed on platelets [68]. GPVI is exclusively expressed in platelets where 
it non-covalently associates with a transmembrane adapter protein, FcRγ [69]. 
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Collagens are the most abundant proteins in the subendothelial matrix. Dimerized 
GPVI has high affinity for collagen [70]. Interaction of GPVI with collagen initiates 
downstream signaling that is important for platelet activation [9]. In addition to 
collagen, convulxin, a C-type lectin venom, is a potent, specific ligand to GPVI and 
induces platelet activation by similar downstream signaling as triggered by collagen 
[71]. 
Integrins 
Integrins are heterodimeric membrane proteins consisting of two subunits, α subunit 
and β subunit, and are cell adhesion receptors mediating the binding of cells to 
extracellular matrix, cell-surface ligands, and soluble ligands [72]. In vertebrate, there 
are 18 α subunits and 8 β subunits, generating 24 heterodimers. The subunits are non-
covalently associated [73, 74]. Usually, integrins have big extracellular domain, a single 
transmembrane domain from each subunit, and small cytoplasmic tail, although the α 
and β subunits have distinct domain structures. Both subunits contribute to the ligand-
binding site in their extracellular domain, with specific binding ligand for individual 
integrin. Integrin functions are regulated by both integrin signaling and integrin 
trafficking, and integrin dysfunction can cause severe diseases like cancer.  
Platelets express multiple integrins for different ligands (Table 1, [75]). In resting 
platelets, integrins are kept in a bent or low-affinity state. Upon platelet activation, 
they are transformed into an extended or high-affinity state.  
Integrin α2β1  
Integrin α2β1 is another collagen receptor (in addition to GPVI) on platelets [76]. It 
plays a role in the adhesion of platelets to collagen and for subsequent optimal 
activation [77]. Deletion of α2 subunit or β1 subunit in mice does not cause bleeding 
defects, although these platelets show minor defects in platelet adhesion and 
aggregation to collagen [77, 78]. However, combined deficiency of α2β1 and GPVI in 
mice causes complete inhibition of thrombus formation [79]. Thus, it is widely 
accepted that α2β1 and GPVI function synergistically for optimal platelet adhesion and 




Integrin α5β1 is the principal platelet receptor for fibronectin [80]. It supports 
adhesion of resting platelet to fibronectin in static conditions [81]. However, α5β1-
fibronectin interaction does not cause platelet tyrosine phosphorylation of focal 
adhesion kinase (FAK), calcium oscillation and lamellipodia formation [81]. Since this 
interaction is sensitive to shear stress, it is thought that α5β1 may play a role in injuries 
in the larger blood vessels where shear forces are low [82].  
Integrin α6β1 
Integrin α6β1 is the principal laminin receptor in platelets [80]. Binding of platelets to 
laminin via α6β1 does not lead to platelet aggregation. But, α6β1-mediated platelet 
adhesion to laminin induces signaling pathways, leading to filopodia formation [81]. 
Integrin αvβ3 
Integrin αvβ3 prefers vitronectin as its ligand, although it can also bind osteopontin 
and fibronectin [83]. It has been shown that integrin αvβ3 mediates platelet adhesion 
to vitronectin and osteopontin in vitro [84]. Integrin αvβ3 support adhesion on 
fibronectin and promote formation of filopodia but not lamellipodia or FAK 
phosphorylation [81]. However, the in vivo role of integrin αvβ3 is unknown.  
Integrin αIIbβ3 
Integrin αIIbβ3 binds several Arg-Gly-Asp (RGD)-containing ligands, including 
fibrinogen (the major ligand), vWF, vitronectin, and fibronectin. It mediates platelet 
aggregation by crosslinking integrin αIIbβ3 on different platelets through fibrinogen, 
and serves as the principle receptor for platelet adhesion in vivo. In human, mutation 
on αIIb and β3 leads to the so-called Glanzmann thrombasthenia (GT) syndrome, a 
bleeding disorder due to quantitative or qualitative defects in αIIbβ3. Deletion of β3 
subunit in mice represents a good model for human GT, having prolonged bleeding 
times, abnormal platelet aggregation and clot retraction [85].  
Platelets and Hemostasis 
Platelets play an essential role in hemostatic plug formation at the vascular injury site, 
in a spatiotemporally coordinated manner [86, 87]. This process can be roughly 
divided into three phases: 1) initiation phase: in which platelets adhere to the exposed 
subendothelial extracellular matrix and are activated, 2) extension phase: where 




















Ligand(s) Other Name Reference 
α2β1 2000 - 4000 Collagen 
CD49b/CD29, VLA-
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[81, 83, 84, 88] 
 
α5β1 2-4000 Fibronectin 
CD49c/CD29, VLA-
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agonists, 3) stabilization phase: where a consolidated hemostatic plug is formed [5, 
89]. 
In the initiation phase, the subendothelial extracellular matrix is exposed. This matrix 
contains several adhesive macromolecules, including collagen, vWF, laminin, 
fibronectin and thrombospondin. They interact with different platelet receptors, 
mediating platelets adhesion to the injury site. Under high shear conditions (>1000 s-
1), as in small arteries, platelets are arrested by interactions between platelet GPIb-IX-
V and vWF [90]. VWF can be synthesized by both endothelial cells and 
megakaryocytes/platelets and stored in Weibel-Palade bodies and α-granules, 
respectively [91-93]. Endothelial cells constitutively secrete their vWF into the plasma. 
At the event of vascular damage, circulating vWF is rapidly recruited to the matrix by 
interactions with collagen. Recently, it has been reported that vWF from endothelial 
cells is sufficient to support hemostasis and vWF from megakaryocytes/platelets can 
also contribute to hemostasis in the absence of EC derived vWF [28]. In contrast, under 
low shear conditions (<1000 s-1), as in veins, adhesion of platelets to subendothelial 
matrix is mediated by collagen, fibronectin, and laminin [94, 95]. Collagen receptors, 
including GPVI and integrin α2β1, are important for platelets to form stable adhesions 
[79]. 
In the extension phase, platelets are activated by different signal transduction 
pathways after stable binding to extracellular matrix. This causes increased cytosolic 
Ca2+, cytoskeletal rearrangement, and integrin activation. The signaling pathways to 
activate platelets include both tyrosine kinase (e.g. GPVI, GPIb complex)-based 
signaling and G protein-coupled receptors (e.g. thromboxane A2, P2Y, PAR receptors)-
based signaling. Upon platelet activation, a controlled release reaction (the fusion of 
platelet granules with plasma membrane) occurs. Platelets contain three main types 
of granules: dense granule, α-granule, and lysosome. The released contents, especially 
the ADP from dense granules, act in a para- or autocrine manner, to quickly amplify 
the platelet activation by activating nearby platelets. α-Granules contents are 
heterogeneous: chemokines, (anti-) angiogenic molecules, growth factors and both 
pro and anti-thrombotic molecules. Thus, the effects induced by α-granule releasate 
are diverse, including: primary hemostasis, coagulation, inflammation, angiogenesis, 
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and wound healing [25]. For hemostasis, released vWF and fibrinogen play roles in 
mediating the cross-linking of platelets via αIIBβ3 and GPIb complex. These 
interactions induce outside-in signaling which leads to further activation of αIIbβ3. It 
is known that there is an intracellular pool of integrin αIIbβ3 and GPVI on α-granule 
membranes [96-99]. Thus, upon α-granule exocytosis, these receptors are exposed on 
plasma membrane, which amplifies the platelet activation process. Dense granules 
contain serotonin, nucleotides, and Ca2+, and play a direct role in platelet amplification. 
ADP secreted from dense granules interacts with two biochemically related purinergic 
G protein-coupled receptors, P2Y1 and P2Y12. Interaction between ADP and P2Y1 
causes platelet shape change and aggregation through Gq-mediated phospholipase C-
β2 activation [100]. Meanwhile, ADP binding to P2Y12 induces sustained platelet 
activation by Gi-mediated inhibition of adenylyl cyclase activity [101]. These two 
receptors are equally required for conversion of free arachidonic acid to the secondary 
activator, TxA2 [102]. The signaling discussed above leads to inside-out activation of 
integrin αIIbβ3 and platelet aggregation, which is facilitated by fibrinogen-mediated 
crosslinking of integrin αIIbβ3 on different platelets.  
In the stabilization phase, irreversible platelet aggregates are formed. Fibrinogen, vWF 
and fibronectin all contribute to the formation of stable platelet aggregates by 
interacting with activated integrin αIIbβ3. Interestingly, mouse lacking both vWF and 
fibrinogen was still able to form fragile thrombi [103]. Wang et al reported that 
fibronectin was the first component deposited onto the subendothelial extracellular 
matrix of damaged vessel and plays an important role for stable thrombi formation in 
mouse [104, 105]. At the last stages, a fibrin network is formed to stabilize the platelet 
thrombus, which is mediated by thrombin-generating coagulation system.  
At the other side of thrombus formation, the inhibitory signaling for platelet activation 
is required to limit the spontaneous platelet aggregation that leads to vessel occlusion 
and potential ischemia. These signaling pathways are also important to limit the 
thrombus size to the site of vascular injury. Nitric Oxide (NO) and prostacyclin (PGI2) 
generated by endothelial cells are strong negative regulators pacifying platelet 
activation [106, 107].  
Platelets and Cancer 
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In additional to the well-recognized role in hemostasis, increasing evidence supports 
that, platelets are also important players in multiple physiological or pathological 
conditions, including inflammation, angiogenesis, and cancer [108]. Although these 
conditions are distinct and unique in their development and progression, platelet 
contributions to these processes have similarity at certain levels.  
The association between platelets and cancer progression has been known for over a 
century as Professor Armand Trousseau reported recurrent migratory 
thrombophlebitis as early as in 1865. However, interactions between tumor cells and 
platelets has only recently been studied more carefully [109]. It has been suggested 
that the ability of tumor cells, e.g. adenocarcinoma cells and SKNMC neuroblastoma, to 
undergo extensive interactions with platelets may be critical for the successful 
metastatic spread of tumor cells [109-111].  
The ability of tumor cells to aggregate platelets, often called tumor cell-induced 
platelet aggregation (TCIPA), is tumor type-dependent, and varies due to the 
mechanisms used.  
Cancer cells can stimulate the release of platelet contents, like ADP, which contributes 
to TCIPA. SKNMC [112] and neuroblastoma small-cell lung cancer [113], breast 
carcinoma [114] and fibroblastoma [115] can mediate TCIPA by tumor cell-dependent 
ADP release from platelets.  
Cancer cells can also stimulate the production and release of thromboxane A2, which 
in turn leads to TCIPA probably by activating platelets through thromboxane receptors. 
It has been shown that TCIPA induced by osteosarcoma can be inhibited by BM-567 
which is the original TXA2 synthase inhibitor and TXA2 receptor antagonist [116]. It has 
also been shown that ketoconazole, a thromboxane synthetase and 5-lipoxygenase 
inhibitor, is able to significantly inhibit thromboxane B2 formation and reduce hepatic 
metastasis from the human pancreatic carcinoma in the nude mouse model [117].  
Cancer cells are able to stimulate TCIPA by generating serine proteinases (e.g. 
thrombin), cysteine proteinases (e.g. cathepsin B), and matrix metalloproteinases 
(MMPs). Human glioblastoma [118], neuroblastoma [119], and pancreatic cancer [120] 
cells can generate thrombin, and thus increase TCIPA. It was shown that cathepsin B 
can be released from cancer cells and mediate TCIPA [121-123]. It has been shown 
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that MMP-2 released from both platelets and cancer cells mediates fibrosarcoma and 
breast adenocarcinoma cells-induced TCIPA [114, 115, 124]. 
Lastly, cancer cells can stimulate TCIPA through adhesion receptors, including GPIb-
IX-V, Integrin αIIbβ3 and P-selectin. It was shown that breast adenocarcinoma cells 
expressed GPIb-IX-V [114, 115], and that inhibition of GPIb-IX-V or vWF with blocking 
antibodies reduced platelet-cancer cell interaction [125, 126]. Integrin αIIbβ3 has 
been shown to play a crucial role in TCIPA induced by cancer cells of various origin 
[114, 121, 125-130]. Interaction between P-selectin and mucin was shown to mediate 
TCIPA in mucin-producing cancers [131-135]. 
Because of these effects of tumor cells on platelets, cancer patients are at higher risk 
for a thrombotic incident. Actually, the risk of venous thromboembolism (VTE), i.e. 
deep venous thrombosis or pulmonary embolism, is four- to sevenfold higher in 
cancer patients compared to healthy individuals [136].  
Conversely, platelets act as a potential cancer modulator affecting tumor growth and 
progression [137]. Platelets play multiple roles in cancer progression, including 
promoting tumor cell proliferation, protecting tumor cells from immune system 
elimination, and helping tumor cells arrest at the vessel wall, supporting the 
establishment of secondary lesions (metastasis).  
Platelets promote tumor growth by releasing many factors that affect angiogenesis, a 
crucial event for tumor growth [138]. These factors could be either anti-angiogenic 
(e.g. angiopoietin 1, sphingosine 1-phosphate, serotonin) or pro-angiogenic (e.g. 
vesicular endothelial growth factor, epidermal growth factor, basic fibroblast growth 
factor). However, how platelets balance the pro-angiogenic effects and the anti-
angiogenic effects remains unclear. It has been suggested that these factors are 
differentially secreted by platelets upon different stimulation [139]. In addition to 
angiogenic factors, other enzymatic molecules secreted by platelets also affect cancer 
progression. Recently, platelet-derived autotaxin (taken up from plasma and stored in 
α-granules) was suggested to play an important role for tumor cell proliferation, 
adhesion, migration and thus metastasis [140].  
Platelets can help the tumor cells survive in the blood stream by forming hetero-
aggregates with tumor cells and leukocytes [138]. Due to the high shear rates and the 
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immune system, the microenvironment in the blood stream is hostile for tumor cells. 
TCIPA leads to formation of a ‘platelet coat’ on the surface of tumor cells and thus 
shields them from immune responses, creating a protective microenvironment [137]. 
After entering the blood stream, hetero-aggregates travel within the circulation and 
then tether and roll along the activated areas of the endothelium. P-selectin from both 
platelets and endothelial cells contribute to these transient interactions [133]. The 
firm arrest on the endothelium is mediated by integrins. Integrin αIIbβ3 plays an 
important role in this process [141, 142].  
At last, platelets could assist tumor cells as they exit the bloodstream and invade 
target organs for metastasis. The release of platelet granule contents and 
microparticles enhances vascular permeability [143, 144], allowing tumor cells to 
cross the endothelial barrier and reach secondary lesion sites. Growth factors (e.g. 
platelet-derived growth factor, VEGF, EGF) [145], small lipids (e.g. S1P, LPA) [146], 
serotonin [143] and histamine [147] were shown to be involved in the regulation of 
vascular permeability for extravasation.  
In summary, platelets are special cells circulating in the blood. They have unique 
structures with different cargo segregated in different granule compartments. They 
express various receptors controlling different signaling. Upon stimulation, they go 
through fundamental changes in the shape and in the intracellular structure to 
perform their functions. Their roles have been extended far beyond their primary role 
in which they arrest blood loss by forming thrombotic plugs; they are actually actively 
involved in various physiological and pathological conditions, including cancer.  
 
Subsection Two: Integrin Signaling and Trafficking 
Integrin Activation  
As discussed above, integrins switch between the bent inactive conformation which 
has low affinity for its ligand, and extended active conformation, which has high 
affinity for its ligand. The shift of the integrin conformation from bent to upright is 
called integrin activation, which could be mediated by either direct binding to 
immobile substrate or by inside-out signaling. Upon integrin activation, outside-in 
signaling will transmit the signal into the cell by binding to its ligand.  
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Integrin inside-out signaling 
There are many cellular proteins that have been reported to be important for integrin 
activation, including talin [148], kindlin [149], Rap1 [150], CalDAG-GEF [151], RIAM 
(Rab1-GTP interacting adaptor molecule) [152] and so on. Talin consists of a large N-
terminal head domain and C-terminal rod domain [153, 154]. The head domain 
contains a PTB domain which has high-affinity for the integrin β tail and is sufficient to 
activate integrin [155]. Moreover, the head domain contains a second binding site for 
the membrane-proximal region of β-integrin cytoplasmic domain, which is required 
for integrin activation. Binding of talin to integrin destabilizes the interaction between 
the αIIb integrin transmembrane domain and the β3 integrin transmembrane domain, 
and thus mediates integrin conformational change and activation. Talin-deficient 
platelets have severe defects in integrin αIIbβ3 activation and platelet aggregation, 
and thus platelet-specific talin knockout mice have spontaneous hemorrhages and 
pathological bleeding [156]. Kindlin is another β-integrin-binding protein that acts as 
a co-activator of talin for integrin activation [157]. Kindlin binds to integrin at a site 
distal to the talin-binding region. There are three isoforms of kindlin, kindlin 1, kindlin 
2 and kindlin 3. Kindlin 3 deficient platelets exhibit defective activation of αIIbβ3 
integrin and impaired aggregation, and thus mice lacking kindlin3 in platelets have a 
thrombosis formation defect in FeCl3-induced injury of mesenteric arteries [158]. 
Another player in integrin activation is Rap1, a small GTP-binding protein. Knockout of 
Rap1b or its exchange factor CalDAG-GEFI in mice results in the partial impairment of 
agonist-dependent fibrinogen binding to αIIbβ3 integrin and defective platelet 
aggregation [159, 160]. Also, Rap1 effector proteins, like RIAM, contribute to integrin 
activation in other cells [152], but not in mouse platelets [161]. A working model for 
integrin activation in platelets is proposed [162] in which thrombin-mediated 
activation of PAR receptors stimulates phospholipid hydrolysis, resulting in the 
generation of inositol triphosphate (IP3) and diacylglycerol (DAG) which leads to an 
increased cytosolic free Ca2+, activation of PKC and CalDAG-GEFI. Following that, Rap1 
is activated, switching from the GDP-bound form to the GTP-bound form. Activated 
Rap1 recruits its effector, RIAM, and its binding partner, talin, to the plasma 
membrane, enabling the interaction between talin and the β3 integrin tail. Kindlin 3 
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seems to be recruited to the β3 integrin tail to strengthen the activation of integrin 
following talin binding.  
Integrin outside-in signaling 
Upon integrin activation and binding to its ligand, integrin outside-in signals are 
transmitted into cells. In cells attaching to the extracellular substrate, integrin outside-
in signaling results in the recruitment of a variety of cytoplasmic proteins to integrin 
and the formation of a structure called focal adhesion which functions as a mechanical 
links between intracellular actin bundles and the extracellular substrate. These signals 
are important for the regulation of cell proliferation, differentiation, etc [163, 164]. 
Integrin cytoplasmic tails, of both α and β subunits, are generally short and lack 
enzymatic activities. Therefore, adapter proteins are required for transducing integrin 
signals to the cytoskeleton, cytoplasmic kinases, and transmembrane growth factor 
receptors. There are many proteins involved in integrin outside-in signaling [165-167], 
including caveolin-1, focal adhesion kinase (FAK), Src-family kinase, paxillin, and Gα13. 
Caveolin-1, an oligomeric membrane protein, has been shown to associate with 
several integrins such as αvβ3 and α5β1 integrins [168-171]. Suppressing caveolin-1 
expression inhibits the formation of focal adhesions, and integrin signaling [172]. It is 
hypothesized that caveolin-1 helps integrin to cluster on the plasma membrane, and 
facilitates concentrating integrin-associated structural and signaling proteins [173, 
174].  
Focal Adhesion Kinase (FAK) behaves as a phosphorylation-regulated signaling scaffold 
and is important for adhesion turnover [175]. Most integrin signals induce the FAK-
mediated pathway [176, 177], although FAK activation is not well understood. 
Association between FAK and β-integrin may be mediated either by direct interaction 
or through the cytoskeletal proteins, talin and paxillin [176]. Upon activation, FAK 
autophosphorylates at Tyr397, creating a binding site for the Src homology 2 (SH2) 
domain of Src and Fyn and thus resulting in phosphorylation of a number of focal 
adhesion components, like paxillin [178, 179]. The activation of these downstream 
effectors links FAK to signaling pathways that modify the cytoskeleton [180] and 
activate mitogen-activated protein kinase (MAPK) cascade [181]. Upon assembly of 
focal adhesions, FAK is phosphorylated on serine, which is different from the previous 
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tyrosine phosphorylation, and disassociates FAK from Src which may lead to a 
loosening of cell-substrate attachments [182]. 
Integrins also partner with growth factor receptors for optimal activation of these 
proteins [183]. It has been demonstrated that appropriate integrin-mediated cell 
attachment is necessary for optimal signaling downstream of the receptors, e.g. 
insulin receptor [184], platelet-derived growth factor (PDGF) receptor [185, 186], 
epidermal growth factor (EGF) receptor [187], and vascular endothelial growth factor 
(VEGF) receptor [188, 189]. Integrins appear to have preferences for the growth 
receptors they associate with. The αvβ3 integrin can be immune-precipitated in 
complexes with receptor for insulin [190] insulin, PDGF [191], and VEGF [192], 
whereas α5β1 integrin associates with the EGF receptor [193].  
The fact that G proteins interact directly with integrin β subunit and regulates integrin-
mediated signaling has been revealed recently [194, 195]. At least two β subunits, β1 
subunit and β3 subunit, are able to interact with Gα13 [195]. Knockdown of Gα13 or 
inhibition of the Gα13 binding leads to inhibition of integrin-dependent activation of 
Src family kinases (SFK) and impairment of integrin-dependent cell spreading. Thus, it 
is likely that Gα13-mediated integrin signaling and cell spreading is through activation 
of SFK. The current model for Gα13-regulated platelet spreading and clot retraction is 
that following binding of the extracellular ligands to integrin αIIbβ3, Gα13-β3 
interaction, and consequent activation of β3-bound c-Src induces c-Src-dependent 
inhibition of RhoA, which is required for cell spreading [196]. During this process, c-
Src phosphorylates β3 at Y747 and Y759, preventing the cleavage of β3 cytoplasmic 
tail by calpain. Subsequent dephosphorylation of β3 integrin Y759 after cell spreading 
allows calpain to cleave β3 cytoplasmic tail, leading to removal of c-Src and freeing the 
inhibitory effect of c-Src on RhoA. RhoA is subsequently activated, initiating contractile 
signaling and cell retraction [195]. However, it is still unclear how the binding of Gα13 
and other signaling molecules to integrin β subunits is coordinated during integrin 
signaling.  
Integrin Trafficking and its Regulations 
Integrin trafficking is another aspect of regulation of integrin function. It was 
discovered in the late 1980s and early 1990s. This work was pioneered by Mark 
16 
 
Bretscher who, using biochemical recycling assays, found that integrin heterodimers 
are continually recycling between the plasma membrane and endosomal 
compartments [197]. It has become increasingly clear that integrin endo-exocytic 
cycling is a rapid, selective, and highly efficient process, which has multiple cellular 
roles, such as mediating uptake of cargo to endosomal compartments and conducting 
cellular processes in a spatiotemporal manner. Consistently, integrin recycling has 
been shown to be an important element in controlling cell migration and tumor cell 
invasion. My dissertation work has attempted to address the role of this process in 
platelet function. 
Integrin endocytosis occurs in both a clathrin-dependent and a clathrin-independent 
manner. For instance, integrin α5β1 and αvβ3 can enter the cell via both clathrin-
dependent endocytosis [198-200] and caveolar-dependent endocytosis [168, 201]. 
Like other receptors following clathrin-dependent endocytosis, e.g. the low density 
lipoprotein receptor, many integrin β subunits contain a NXXY motif in their 
cytoplasmic domain. This mediates the recruitment of adaptor proteins for clathrin-
coated pit formation. However, it is interesting that disruption or depletion of the 
NXXY motifs in the β3 cytoplasmic domain did not affect the internalization of β3 
integrins, αIIbβ3 and αvβ3 [202], implying a potential role for the α subunit in the 
endocytosis process. Integrins could also be internalized via a caveolin-dependent 
process, which is dynamin-dependent and linked to the activation of protein kinase C 
(PKC)-α. Indeed, several integrins including αvβ3 and α5β1 are found to associate with 
caveolin-1 or with detergent-resistant membrane domain that contain caveolin [168, 
169, 201, 203]. Moreover, both dynamin and PKC-α are found required for β1 integrin 
internalization [204, 205] and dominant negative dynamin expression has been shown 
to block disassembly of β1 integrin-containing focal adhesions [206], possibly by the 
disruption of a dynamin-dependent internalization of this integrin.  
After internalization, integrins are recycled back to plasma membrane via two 
temporally and spatially distinct mechanisms, a short-loop and a long-loop [204]. After 
reaching early endosomes (EEs), integrins selected for short-loop recycling are sorted 
to particular subdomains of EEs and then rapidly returned to the plasma membrane 
in a Rab4-dependent manner. Alternatively, integrins may pass from EEs to the 
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perinuclear recycling compartment (PNRC), from where they return to the plasma 
membrane under control of the Rab11 GTPase, referred as long-loop.  
The Rab11-positive PNRC accommodates a range of integrins (e.g. β1 integrins [207-
209], αvβ3 [208, 210], and α6β4 [210], growth-factor/cytokine (CXCR2) [211], TGFβ-R 
[212], EGF receptors [213], transferrin receptor (TFN-R) [214] and other receptors 
[215]. Current studies demonstrate that PKB/Akt mediates the recycling of α5β1 and 
αvβ3 integrins, but not TFN-R, from PNRC to PM via the phosphorylation of GSK-3β 
[208], suggesting the selective recycling of integrins can be modulated by certain 
signaling pathways. It becomes clear that ADP-ribosylation factor 6 (Arf6) regulates 
the exit of β1 integrins from PNRC in conjunction with Rab11 [216]. It is interesting 
that effectors of Rab11 (FIP3 and FIP4) also bind to Arf [217].  
In contrast to Rab11-dependent long-loop recycling of integrins back to PM, short-
loop recycling requires Rab4. In fibroblasts treated with platelet-derived growth factor 
(PDGF), αvβ3 integrin is diverted into short-loop recycling pathway [218]. Moreover, 
the PKC-related kinase, PKD1 is required for short-loop recycling of αvβ3 [219], while 
mutant αvβ3, that is unable to bind to PKD1, does not recycle in response to PDGF. 
Supportively, proteomic studies indicate that PKD1 associates with an αvβ3 complex. 
Arf6 has been demonstrated to mediate the short-loop recycling of integrins in 
neuronal cells [220].  
Integrin trafficking plays an important role in cell adhesion, migration, and tumor cell 
invasiveness. It has been shown that blocking all endosomal membrane recycling and 
Golgi transport by primaquine causes rapid disappearance of cycling adhesion 
receptors from the cell surface and consequent detachment of cells from the 
substratum. Selective inhibition of long-loop recycling by targeting Rab11, Arf6, or 
myosin Vb impairs migration and/or chemotaxis in a number of different cell types 
[211, 216]. Similarly, inhibiting short-loop recycling of αvβ3 by expressing dominant 
negative Rab4 reduces cell spreading on vitronectin, an αvβ3 ligand [221]. To address 
the specific role that integrin trafficking has in these processes, the cytoplasmic 
domain motifs of integrin were targeted since these motifs regulate integrin function 
during cell migration. It was shown that disruption of a YXXѲ motif in the membrane 
proximal region of the β2 integrin cytoplasmic domain has no effect on the receptor’s 
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adhesive functions but impairs the recycling of αLβ2, leading to reduced cell migration 
on intercellular adhesion molecule-1 (a ligand for αLβ2) but not on other ligands, such 
as fibronectin [222]. The contribution of integrin endo-exocytosis trafficking to cell 
migration could be from 1) the simple return of binding competent integrins to the 
cell surface; of 2) the spatial redistribution of integrins toward the cell’s leading edge.  
The role of integrin trafficking in cancer growth and invasiveness has been 
demonstrated through the connection of the RabGTPase and kinases responsible for 
controlling integrin recycling to cancer. The tyrosine kinase, Src, well-known for 
promoting cell transformation, is recruited to the plasma membrane by a Rab11-
controlled recycling pathway [223]. Moreover, Rab11-FIP3 has been identified as 
tumor marker [224]. Consistently, a number of proteins, which regulate integrin 
trafficking, e.g. Arf6 [225], PKD1 [219], and dynamin [226], are abundant in the 
invadopodia of aggressive cancer cells. Integrins could also contribute to cancer cell 
invasiveness by directing MT1-MMP and uPAR/uPA, membrane-associated proteases, 
to invadopodia [227].  
Integrin αIIbβ3 Trafficking in Platelets 
Integrin αIIbβ3 cycling in platelets back and forth between plasma membrane and 
intracellular vesicles has been recognized for about two decades [228]. αIIbβ3 
localizes in various cellular locations, including plasma membrane, α-granules [97], 
and dense-granules [229]. In fact, many platelet membrane proteins are present on 
both the plasma membrane and α-granules, e.g. integrins, immunoglobulin family 
receptors [99], leucine-rich repeat family receptors [230], tetraspanins [230], and 
other receptors (e.g. CD36) [231]. Due to the fact that the abundance of plasma 
membrane receptors reside in α-granule membranes, it has been suggested that 
endocytosis of plasma membrane contributes to the presence of adhesion molecules 
in α-granules [232]. It is well established that fibrinogen in α-granules is derived from 
plasma and the uptake process is mediated by integrin αIIbβ3 [29]. Therefore, 
fibrinogen content in α-granules is a good indication of trafficking of integrin αIIbβ3. 
However, the molecular machinery regulating the trafficking of integrin αIIbβ3 is 
largely unknown. Electron microscopy experiments suggested that integrin αIIbβ3 
trafficking in platelets is a clathrin-dependent process [233]. Consistently, the clathrin-
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associated adaptor proteins AP-1, AP-2 and AP-3 are found in platelets [234]. 
Interestingly, unlike other cells, the clathrin coat on the coated vesicles in platelets is 
retained throughout trafficking and for a period after fusion with α-granules [235]. 
Moreover, Src-family kinases may also play an important role in the endocytosis 
process in platelets based on the observation of co-localization of Src-family kinase 
with clathrin [235]. In fact, a knockout of lyn, a member of Src-family, in mouse 
platelets increased the surface level of αIIb integrin [236]. Recently, disabled-2 (DAB-
2), an endocytic adaptor protein, was suggested to be required for cellular uptake of 
fibrinogen in megakaryocyte cell lines (Hung WS 2012). However, DAB-2 deletion in 
mouse platelets had only mild effects on fibrinogen uptake with only a 20% decrease 
in platelet fibrinogen levels [237]. This suggests that DAB-2 plays a limited role in 
integrin αIIbβ3 trafficking in platelets and may contribute to other aspects of integrin 
function.  
Integrin αIIbβ3 trafficking in platelets is fast. Abciximab or c7E3 Fab, an antagonist to 
integrin αIIbβ3, is detectable within 3 hours post-infusion into a patient [233]. It 
requires much shorter time for abciximab to be detectable in vitro after incubation 
with washed platelets. It was suggested that the OCS is the entry site for these 
exogenous substances. Indeed, OCS channels were stained as early as 1 minute [238], 
suggesting a rapid diffusion of c7E3 into the internal platelet compartment, which is 
consistent with other reports. Studies using monoclonal antibody AP6 [239], which 
binds to integrin αIIbβ3 only when the receptor is occupied by intact fibrinogen, 
suggested the presence of a pool of ligand-bound αIIbβ3 in the α-granule membrane. 
Also, thrombin induced activation of the internal integrin αIIbβ3 prior to the surface 
pool, and then induced the exposure of αIIbβ3-ligand complexes to the surface. In fact, 
platelet activation by ADP or thrombin receptor activation peptide (TRAP) significantly 
increases the actin cytoskeleton-dependent internalization of αIIbβ3 [240]. Also, 
direct activation of αIIbβ3 with an anti-LIBS antibody caused an approximate 8-fold 
increase in the extent of receptor internalization. Consequently, upon stimulation 
while the stirring is delayed, internalization of fibrinogen-bound receptor complexes 
reduced platelet aggregation [241]. In summary, integrin αIIbβ3 trafficking is a 
continuous process in platelets that appears to play an important role in deposition of 
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α-granule cargo, like fibrinogen, and in modulation of platelet aggregation. However, 
it is unclear whether integrin trafficking plays roles in other integrin-mediated platelet 
functions, like spreading, clot retraction. Moreover, there is little known about the 
molecular mechanism(s) regulating the trafficking of integrin αIIbβ3. 
 
Subsection Three: ADP-ribosylation Factor (Arf) 
Arf Family 
The Arf family of small GTP-binding proteins belongs to Ras superfamily [242, 243]. 
Like other Ras-related proteins, members of the Arf family cycle between a GDP-
bound inactive form and a GTP-bound active form. The Arf family includes Arf proteins, 
Arf-like (Arl) proteins and Sar1. There are 6 mammalian Arf proteins that can be 
divided into three classes based on homology of primary protein sequence: Class I 
(Arfs 1-3), Class II (Arfs 4-5), and Class III (Arf6). They are all ubiquitously expressed 
and their amino-acid sequences seem to be well conserved in all eukaryotes, however, 
humans do not express Arf2. There are over 20 Arl proteins expressed in different 
systems, and Sar1 is present in all eukaryotes. For my thesis work, I focus on Arf 
proteins, particularly Arf6, the most divergent Arf protein. 
Arf proteins were originally discovered as cofactors for cholera-toxin in catalyzing 
ADP-ribosylation of the α-subunit of heterotrimeric G proteins, Gs, in cell-free 
biochemical assays [244]. They have multiple cellular functions, including the 
recruitment of coat proteins that promote sorting of cargo into vesicles, the 
recruitment and activation of lipid-modification enzymes, actin cytoskeleton 
rearrangement, and membrane trafficking [245].  
The cellular compartments in which Arfs reside include the plasma membrane, and 
the membranes of the secretory and the endosomal/lysosomal pathways, and the 
cytosol. The amino-terminus of Arfs features an amphipathic helix and myristoylation 
at the second glycine residue, which are both critical for membrane localization [246]. 
Upon GTP-binding, the myristoyl group and associated amphipathic helix are flipped 
out and inserted into the membrane, causing very close contact of Arfs with the 
membrane [247]. It seems that Arf1 and Arf3 are released from the membrane upon 
GTP hydrolysis in cells [248], while GDP-bound Arf6 still remains at the membrane 
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[249]. Arf1 and Arf6 are the most studied members of Arfs. Arf1 functions in 
transportation between the Golgi and Endoplasmic Reticulum (ER), while Arf6 
functions between the plasma membrane and endosomal vesicles [242]. Despite the 
unique subcellular localizations of Arf1 and Arf6, they share similar functions as 
discussed below for Arf6. 
Arf6 and Phospholipid Metabolism 
The effect of Arf6 on membrane phospholipid modification is mediated by activation 
of two important phospholipid enzymes, phosphatidylinositol 4-phosphate 5 kinase 
(PIP5K) [250] and phospholipase D (PLD) [251-253]. PIP5K catalyzes the 
phosphorylation of phosphatidylinositol 4-phosphate [PI(4)P] at the D5 position of the 
inositol ring to produce the versatile lipid messenger phosphatidylinositol 4,5-
bisphosphate [PI(4,5)P2]. Honda et al. [250] shown that Arf6 directly activates PIP5K 
in phosphatidic acid-dependent manner, and, via PIP5K, Arf6 regulates various cellular 
functions by locally increasing the concentration of PI(4,5)P2. First, PI(4,5)P2 could 
serve as a precursor of lipid second messengers. PI(4,5)P2 is hydrolyzed by 
phosphatidylinositol-specific phospholipase C to generate two lipid second 
messengers, diacylglycerol (DG) and inositol 1,4,5-triphosphate (IP3), which in turn 
activates protein kinase C and increases intracellular Ca2+, respectively. Second, 
PI(4,5)P2 could be further phosphorylated by phosphatidylinositol 3-kinase, 
generating another lipid second messenger phosphatidylinositol 3,4,5-triphosphate 
which is important for cell growth, survival and apoptosis [254, 255]. Lastly, PI(4,5)P2 
itself could act as a signaling molecule by regulating the activities of target proteins 
and enzymes or by recruiting them to certain areas of specific subcellular 
compartments. 
Indeed, Arf6/PIP5K signaling has been demonstrated to play various cellular functions 
via PI(4,5)P2. Arf6/PIP5K is directly involved in PI(4,5)P2-dependent exocytosis, 
including insulin secretion in MIN6 pancreatic cells [256], dense core vesicle exocytosis 
in PC-12 neuroendocrine cells [257], and neurotransmitter release from 
synaptosomes prepared from rat brain [258]. Arf6/PIP5K signaling also regulates 
clathrin-dependent endocytosis of synaptic vesicle by recruiting adaptor complex AP-
2 to synaptic membranes [259, 260]. Moreover, the Arf6/PIP5K signaling pathway 
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plays a key role in endocytic trafficking. Overexpression of an constitutively active Arf6 
mutant in Hela or COS cells results in accumulation of internalized vesicles and 
subsequent formation of elongated vacuolar structures [261], which mirrors the 
phenotype seen by overexpressing wild type PIP5K. Conversely, overexpression of a 
dominant negative Arf6 mutant blocks the transport of the recycling endosome to the 
plasma membrane [262, 263]. These observations suggest that the inactivation of Arf6 
and thus the decreased level of PI(4,5)P2 on the internalization vesicles are essential 
for formation of recycling endosomes, and that re-activation of Arf6 and subsequent 
PIP5K activation are critical for the endosomal recycling trafficking to and/or fusion 
with the plasma membrane. Also, the Arf6/PIP5K signaling complex plays an important 
role in the actin cytoskeleton reorganization responsible for neurite elongation by 
recruiting the actin-binding protein Mena [264], possibly through PI(4,5)P2.  
PLD is another lipid modification enzyme that is regulated by Arf6. PLD catalyzes the 
hydrolysis of phosphatidylcholine to generate phosphatidic acid (PA) and choline. PA 
plays various cellular roles, including exocytosis [265] and endocytosis [266] and 
reorganization of the actin cytoskeleton [267, 268]. There are two mammalian PLD 
genes, each capable of generating two splice variants [269, 270]. It has been 
demonstrated that PLD activation is mediated by the Rho family, the Arf family and 
the protein kinase C family (PKC) [271]. Single members from each of these activator 
families function in a cooperative way to increase PLD1 activation in vitro [271]. The 
direct interaction between Arf6 and PLD in vivo is suggested by surface plasmon 
resonance experiments [253] and it appears that PLD1b can concurrently interact with 
a single member from each regulator family in vivo [252]. In contrast to PLD1, it seems 
that PLD2 activity is less directly regulated by GTPases but is controlled via interaction 
with PIP5K [272].  
Consistent with PA’s role, Arf6/PLD signal complexes are involved in various cellular 
processes. Arf6/PLD1 has been shown to regulate the stimulation-regulated 
exocytosis in Chromaffin cells [273]. In Hela cells expressing an Arf6 mutant that are 
defective in activating PLD, Arf6N48R and Arf6N48I, block membrane recycling to the 
plasma membrane and induce accumulation of tubular endosomal membranes, 
suggesting that Arf6/PLD plays a role in endosomal membrane recycling [274]. In 
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addition to the roles in membrane trafficking, Arf6/PLD is involved in other cellular 
processes. Recently, it was found that Arf6/PLD promotes autophagosome formation 
by influencing endocytic uptake of plasma membrane into autophagosome precursors 
[275]. Also, Arf6 was demonstrated to play a role in cancer cell proliferation in a PLD-
mTORC1- and p38MAPK (mitogen-activated protein kinase)-dependent manner [276]. 
Arf6 and Actin Cytoskeleton Reorganization 
Arf6 regulates actin cytoskeleton rearrangement in different ways under different-
conditions. Arf6 could trigger actin assembly at the membrane indirectly by recruiting 
the Arf guanine nucleotide exchange factor (GEF) ARNO that activates Arf1 to enable 
WRC [the WASP family veroprolin homolog (WAVE) regulatory complex]-dependent 
actin assembly [277]. This pathway is important for the invasion of the pathogen, 
Salmonella, into host cells. In Hela and CHO cells, Arf6 mediates the redistribution and 
activation of endosome-localized Rac1 to the plasma membrane [278, 279]. Upon 
stimulation by physiological stimuli, Arf6 in CHO cells facilitates the redistribution of 
Rac1 to the cell surface while inhibition of RhoA-mediated formation of stress fiber 
[280]. Arf6 can also modulate the actin cytoskeleton through its effect on lipid 
modification enzymes, PIP5K and PLD as discussed earlier. The direct or indirect lipid 
product, PI(4,5)P2, has been shown to regulate actin capping and the activities of 
several actin-binding proteins [250, 261]. Using a chimera protein Arf1-6 (with the 
amino half of Arf1 and the carboxyl half of Arf6) which is unable to induce the 
formation of actin-containing protrusions, Al-AWAR et al. showed that substitution of 
two residues in the amino-terminal half of Arf6, Q37 and S38, into the chimera could 
result in formation of protrusions, suggesting that the functions of Arf6 in actin 
reorganization is controlled through specific sequence in Arf6 [281]. Arf6-mediated 
actin rearrangement is important for various cell functions, including cell spreading 
[282, 283], formation of pseudopods and membrane ruffles [278, 284], migration 
[285-287], and phagocytosis [288-291]. 
Arf6 and Vesicle Trafficking 
Arf6 is well known for its role in endocytic trafficking, including the endocytosis 
pathway and the endocytic recycling pathway. Indeed, Arf6 are reported to participate 
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in many steps in the membrane trafficking, including recruitment of coat proteins, 
coated pit assembly, vesicle fission, and vesicle route.  
Arf6 in endocytosis pathway 
As discussed earlier, Arf6 activation could lead to activation of lipid modification 
enzymes, PLD and PIP5K, resulting in the local accumulation of PI(4,5)P2 rapidly. It is 
well established that PI(4,5)P2 is one of the most important lipids regulating clathrin 
mediated endocytosis [292]. It has been shown that Arf6-mediated increase of 
PI(4,5)P2 by PIP5K leads to the recruitment of clathrin coats in synaptic vesicle 
preparations [259]. The role of Arf6 in coated-pits assembly was convincingly 
demonstrated by the evidence that Arf6-GTP and PI(4,5)P2 function synergistically to 
recruit AP-2 onto liposomes [293]. At the lateral membrane of MDCK cells, an 
epithelial cell line, Arf6 binds to and recruits NM23-H1 [294], a nucleoside diphosphate 
kinase that functions as a GTP source for dynamin-dependent vesicle fission [295]. It 
has also been shown that Arf6-mediated activation of NM23-H1 plays an essential role 
in the internalization of P2Y purinoceptor receptors, a G protein-coupled receptor, in 
human platelets [54]. Blocking Arf6 activation inhibits P2Y receptor endocytosis, 
resulting in a failure to cycle between desensitization and resensitization in platelets. 
Arf6 is also involved in the internalization of other GPCRs, including β2-adrenergic 
receptor [296] and luteinizing hormone receptors [297]. Therefore, it is clear that Arf6 
has an established role in in clathrin-mediated endocytosis.  
Arf6’s roles in other types of endocytosis process are also reported. It seems that Arf6 
association with caveolae-enriched membrane fractions is important for signaling 
initiated by Hepatocyte growth factor (HGF) [285], vascular endothelial growth factor 
[298] and oncogenic H-Ras [299], because inhibition of Arf6 activity diminishes these 
signaling events. In addition to the endocytosis of GPCR and GFR (growth factor 
receptor), Arf6 also regulates the internalization of ligands through a unique clathrin- 
and caveolae-independent pathway [300]. These ligands include the major 
histocompatibility complex class I protein (MHC class I), M2-muscaranic acetylcholine 
receptors, the β1 integrins and the peripheral myelin-membrane protein (PMP22). 
After ligand internalization, Arf6 and other membrane components are recycled back 
to the cell surface, while cargo ligands, via the classic endocytic pathway, are further 
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sorted [301]. Arf6 inactivation seems to be required for this pathway [261]. Therefore, 
Arf6 participates in receptor internalization through the clathrin-dependent, the 
caveolae-dependent, and the clathrin- and caveolae-independent pathways.  
Arf6 in endocytic recycling 
Most of membrane components that are internalized by clathrin-dependent or -
independent endocytic pathways are recycled back to the plasma membrane, either 
directly from the sorting endosome, a “fast” recycling route, or from a juxtanuclear, 
endocytic recycling compartment (ERC), a “slow” recycling route [302, 303]. In 
addition to Arf6, Rab GTPases also participate in the recycling processes. Among them, 
Rab4 and Rab11 localize to sorting endosomes and ERC, respectively, and function as 
important regulators for each recycling route [304-306]. Arf6’s role in endosome 
recycling was first identified in Chinese Hamster Ovary (CHO) cells, where dominant 
negative Arf6 mutant affected the recycling of surface markers, such as MHC class I 
and ectopically expressed Tac antigen, but not the recycling of classic recycling protein, 
Transferrin receptor (TfR) [307, 308]. In contrast, in Hela cells, Arf6 plays a role in the 
fast, microtubule-dependent endocytic recycling of TfR by interaction with JNK-
interacting proteins 3 and 4 (JIP3 and JIP4). Additionally, Arf6 in Hela cells also 
regulates the recycling of integral plasma-membrane proteins that lack cytoplasmic 
AP-2 and clathrin-sorting sequences, including the IL2 receptor α-subunit, MHC class 
I, and glycosylphosphatidylinositol (GPI)-anchored protein [262, 301]. These 
observations suggest that Arf6 can have different functions in different cell systems.  
Arf6’s role in the fast recycling pathway was also reported in the regulation of β2-
adrenergic receptor (β2AR), a member of the GPCR, β1 integrins and others [220, 309, 
310]. Arf6 activation by β-arrestin, upon the engagement of ligand with β2AR, leads 
to accumulation of β2AR in the degradation pathway and plays a negative role in Rab4-
dependent fast recycling of β2AR for resensitization [309]. In neuronal cells, Arf6 
regulates rapid axonal transport of α9β1 integrin and their trafficking at the cell 
surface. Arf6 activation enhances the integrin endocytosis but decreases axon growth, 
while Arf6 inactivation promotes the recycling of integrin and increases axon growth 
[220]. Arf6 also acts as an upstream negative regulator of Rab35-mediated fast 
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endocytic recycling pathway which is essential for cytokinesis. However, this Rab35-
mediated pathway is not Rab4-positive [310].  
In addition to the roles in the fast recycling, Arf6 is also involved in the slow recycling 
pathways and thus for diverse cell functions, including cell movement, cell adhesion 
and junction formation, cytokinesis, cell polarity, lipid homeostasis and cell fusion. 
[303, 311]. The slow recycling route is vesicle trafficking from a juxtanuclear, endocytic 
recycling compartment (ERC) to plasma membrane. The ERC is a tubular compartment 
having a resident marker protein, Rab11.  
Arf6 and Rab11-mediated recycling of endosomal membrane is required for 
cytokinesis in several organisms, including vertebrates and invertebrates. In cultured 
mammalian cells, Arf6 is important for severing the final intercellular bridge during 
abscission, although it has less effect on furrowing [312, 313]. It is proposed that active 
Arf6 interacting with the exocyst mediates the tethering of Rab11-FIP3/4 containing 
recycling endosomes to the cleavage furrow/midbody. During abscission, the last step 
of cytokinesis, Arf6 was also suggested to regulate the endocytic trafficking direction 
by controlling the interactions of its downstream effectors, JIP3 and JIP4 (JNK-
interacting proteins) with the motor proteins of opposing direction. In Drosophila 
spermatocytes, Arf6 is required during the early and late phase of cytokinesis [314].  
E-cadherin trafficking is important for cell adhesion and morphogenesis. Both Arf6 and 
Rab11 are thought to be regulators of E-cadherin recycling from endosomes to the 
plasma membrane [285, 315]. Activation of Arf6 causes loss of adherens junction, 
leading to increased epithelial cell migration.  
Arf6 and Integrin Trafficking 
In cancer cells, active β1 integrin and inactive β1 integrin traffic through different 
endocytic recycling routes, although their endocytosis requires a same clathrin- and 
dynamin-dependent process [316]. Inactive β1 integrins are recycled to the plasma 
membrane through a Rab4a- and actin-dependent Arf6-positive compartment. It is 
unclear whether Arf6 is required for this process. In Hela cells, depletion of BRAG2, a 
GEF for Arf6, inhibits β1 integrin endocytosis whereas depletion of Arf6 inhibits β1 
integrin recycling back to surface, suggesting that Arf6 may function on both 
endocytosis and recycling pathways of β1 integrins [317]. As a consequence, 
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knockdown of BRAG2 enhances cell adhesion and spreading, whereas knockdown of 
Arf6 inhibits cell spreading. Arf6 activation is also suggested to mediate the recycling 
of integrin-containing lipid rafts to the plasma membrane, and thus influences cell 
adhesion [318].  
Arf6 is also involved in integrin trafficking in stimulated cells. In starved Hela cells, β1 
integrins are recycled to the plasma membrane upon external stimulation upon serum 
addition, a process that is Arf6-, Rab11- and actin- dependent but Rab4-independent 
[216]. In these cells, β1 integrins are internalized to Arf6- and Rab11- positive 
compartment. External stimulation mediates the recycling of integrins to Arf6-
enriched membrane ruffles. This Arf6-GTP-regulated integrin recycling is important for 
cell migration. In contrast, Arf6 activation in endothelial cells is reported to play a role 
in semaphorin 3E-stimulated integrin endocytosis, leading to disassembly of focal 
adhesion, retraction of filopodia, and inhibition of angiogenesis [319]. In summary, 
Arf6 plays a role in both endocytosis and recycling of integrins, regardless in resting 
cells or in stimulated cells, although Arf6 has different functions in different context. 
Given the vast effects of Arf6 discussed above, Arf6 global KO mice exhibit defective 
liver development, due to impairment in hepatic cord formation [320].  
Arf6 Regulators, GEFs and GAPs 
As other Ras GTPases, Arf6’s role is regulated by its cycle between active GTP-bound 
state and inactive GDP-bound state. This cycle is regulated by two classes of proteins, 
guanine-nucleotide-exchange factors (GEF) mediating the loading of GTP on Arf6, and 
GTPase activating proteins (GAP), catalyzing the hydrolysis of GTP to GDP by Arf6. 
Given the diverse functions of Arf6, it is not surprising that its regulators are also 
diverse.  
Arf6 GEFs 
All Arf GEFs contain a conserved Sec7 catalytic domain in, which is named based on its 
homology to the yeast ArfGEF, sec7p [321, 322]. Therefore, Arf GEFs are also called a 
Sec7 family. In mammals, there are 15 Sec7 family members, which could be divided 
into five classes based on overall structure and domain organization [323]. They could 
also be grouped into Brefeldin A (BFA)-sensitive and BFA-insensitive members. BFA is 
a fungal toxin that binds tightly to the Arf-GDP-Sec7 domain complex and thus 
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sequesters the GEFs in an abortive reaction intermediate [324-326]. The Sec7 domain 
consists of approximately 200 amino acids. Crystal structures of this domain alone and 
the complex of Sec7 domain/Arf have revealed the details of the nucleotide exchange 
process, in which the glutamic finger from Sec7 domain is essential for the catalytic 
reaction [324, 327-329]. So far, all Arf6 GEFs identified are resistant to BFA due to the 
fact that Arf6 cannot accommodate BFA in its interface with GEFs [330]. The five 
families include Golgi BFA-resistance factor 1/BFA-inhibited GEF (GBF/BIG), Arf 
nucleotide binding site opener (ARNO)/cytohesin, exchange factor for Arf6 (EFA6), 
Brefeldin-resistant Arf GEF (BRAG) and F-box only protein 8 (FBX8). Among them, the 
cytohesin family [331-333], the EFA6 family [334, 335], and the BRAG family [317, 336-
338] are reported to have Arf6 GEF activity. 
Cytohesin family 
There are four isoforms in the cytohesin family, cytohesin 1 - 4. They are relatively 
small (45-50 KD) and share a common domain organization consisting of an N-terminal 
coiled-coil domain, a central Sec7 domain followed by a PH domain and a short C-
terminal extension rich in positively charged amino acids. They are ubiquitously 
expressed [339] and are primarily localized to the cell periphery [340]. In response to 
PI3K signaling, they can be acutely recruited to the plasma membrane [341, 342]. 
Cytohesin family members are ambiguous to the Arf specificity. In biochemical assays, 
Arf1 is the preferred substrate over Arf6 [340, 343-346]. However, in cells, ARNO can 
activate Arf6 and is recruited to the plasma membrane where Arf6 is localized [287, 
340, 347]. Interestingly, ARNO, via its PH domain but not Sec7 domain, was recruited 
to by Arf6-GTP and, in turn, recruited and activated Arf1 at the PM [348]. Cytohesin-2 
has been shown to promote both the migration of epithelial cells [287] and the 
outgrowth and branching of neurites [264, 349]. Cytohesin-2 has also been implicated 
in vesicular transport [296, 350, 351]. Recently, Torii and colleagues showed that 
expression of cytohesin-1 in Schwann cells in mice increases Arf6-GTP level in these 
cells, and enhanced myelin thickness [331], suggesting the GEF activity of cytohesin-1 
on Arf6 in animals.  
Proteomics study has shown that cytohesin-2 is present in human platelets [352]. 
Consistently, Arf6 was shown to be able to co-immunoprecipitate (IP) cytohesin-2 in 
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resting platelets and this interaction was decreased upon platelets activation [353]. 
Pretreatment of platelets with cytohesin inhibitor, SecinH3, enhanced dense core 
granule secretion. In another study, SecinH3 was shown to inhibit Arf6 activation upon 
P2Y receptors activation and thus to inhibit internalization of P2Y receptors [54]. 
Regardless of the discrepancy between these two studies, these results implicated a 
role for cytohesin in platelet functions.  
EFA6 family 
The EFA6 family in mammals consists of four isoforms, EFA6A, EFA6B, EFA6C, and 
EFA6D. They are characterized by a variable N-terminal region, a central Sec7 domain 
paired with a PH domain, and a coiled-coil motif containing C-terminal domain. EFA6A 
and EFA6C are predominantly expressed in the brain [336, 354]. EFA6B and EFA6D are 
more widely expressed [355]. Compared to the cytohesin family, the EFA6s are 
selective for Arf6 in cell-free assays and in cells [356]. The EFA6s also appear to interact 
selectively with PI(4,5)P2, consistent with their PM localization [354]. Like Arf6, EFA6 
family regulates membrane trafficking and the actin cytoskeleton [356, 357]. The EFA6 
family, via activation of Arf6, plays various roles, including spine formation in dendritic 
cells [334], E-cadherin-mediated tight junction formation and stability [335, 358], and 
cytokinesis [359]. However, EFA6 was not detected by proteomics in human platelets 
in a recent study [352]. 
BRAG family  
The last Arf6 GEFs discussed are members of the BRAG family. The BRAGs consist of 
an IQ-like domain, a central catalytic domain, and adjacent PH domain and C-terminal 
coiled-coil domain. In mammals, BRAG1 and BRAG3 are primarily expressed in the 
brain [360, 361] while BRAG2 is much more widely distributed [362]. BRAGs also 
behave as GEFs for Arf6 in cell-free assays and in cells [317, 362]. Although both BRAG1 
and BRAG3 mainly function in the post-synaptic area, it seems that BRAG1 is at 
excitatory synapses and BRAG3 is at inhibitory synapses [338, 363]. BRAG2 acts as a 
downstream effector of AMPA receptor signaling, regulating endocytosis of AMPA and 
thus long term depression [364]. In endothelial cells, BRAG2 regulates the endocytosis 
of α5β1 integrin, mediating the disassembly of α5β1-containing focal adhesions and 
sprouting of endothelial cells [365]. BRAG2-mediated endocytosis of β1 integrins is 
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also important for cell motility [317]. BRAG2 also contributes to tumor cell metastasis 
by cooperating EGFR signaling and Arf6 activation [366, 367]. However, BRAG family 
was not detected by proteomics in human platelets in recent study [352]. 
Arf6 GAPs 
Like Arf GEFs, all Arf GAPs contain a catalytic domain, called the ArfGAP domain which 
was first identified in rat ArfGAP1 [368] and is highly conserved. ArfGAP domains are 
about 130 amino acids in length and contain a characteristic C4-type zinc finger motif 
and a conserved arginine that is required for activity, within a particular spacing 
(CX2CX16CX2CX4R). Arf GAPs display various degrees of specificity for the individual Arf 
family member both in vitro and in vivo. Based on sequence similarities of their ArfGAP 
domains, the 31 predicated human Arf GAPs have been divided into 10 subfamilies, 
including subfamilies of ArfGAP1, ArfGAP2, ADAP, SMAP, AGFG, GIT, ASAP, AGAP, 
ACAP and ARAP [369]. In the discussion that follows, subfamilies including ADAP, ASAP, 
ARAP, and ACAP will be described as these ArfGAPs have been studied more as Arf6 
GAP proteins. GIT family proteins will be discussed in more details in an independent 
chapter.  
ADAP subfamily 
This subfamily consists of two members, ADAP1 and ADAP2. They are characterized 
as two PH domains immediately C-terminal of the ArfGAP domain. ADAP1 has high 
affinity to PI(3,4,5)P3 and Ins(1,3,4,5)P4 [370, 371], and was thought to be involved in 
PI3K-mediated cellular pathways [372]. It is a brain-enriched protein and localizes to 
the cytosol and nucleus [373]. It could be recruited to the PM in a PIP3-dependent 
manner and functions as an Arf6 GAP protein regulating actin cytoskeleton 
organization [374]. ADAP1 has been reported to interact with various proteins, 
including Arf proteins [375], F-actin [375], KIF13B (a member of the kinesin 
superfamily, [376], Nardilysin (NRDc, N-arginine dibasic convertase, [377]) RanBPM 
(Ran binding protein in microtubule-organizing center, [378]), nucleolin [379], and 
casein kinase 1 [380, 381]. Consistent with that, ADAP1 plays multiple cellular 
functions, such as actin cytoskeleton reorganization [382], GPCR endocytosis [383], 





Three human ASAPs share multiple domains, including a Bin/Amphiphysin/Rvs (BAR) 
domain, a PH domain, an Arf GAP domain, ANK repeats, and a proline-rich (Pro) 
domain, but differ in their C termini [369]. The BAR domain in ASAP1 negatively 
regulates its GAP activity [386] and binding of the BAR domain to FIP3, a Rab11 
effector, stimulates its GAP activity [387]. ASAP1 and 2 prefer Arf1 and Arf5 to Arf6 in 
vitro [388, 389]. In vivo, overexpression of ASAP1 decreases Arf1-GTP level while 
increases Arf6-GTP level [390, 391]. However, there is other evidence showing that 
ASAP1 and ASAP2 also function with Arf6 through direct binding and slow catalysis 
[392, 393]. The crystal structure of Arf-ASAP suggests the importance of Ca2+ in the 
GAP activity [394], in an PI(4,5)P2- and PA-dependent manner [388, 395]. ASAP1 has 
been shown to interact with Src, CrkL, FAK, CD2AP and CIN85 [396]. ASAP2 interacts 
with pyk2, a focal adhesion kinase, whereas ASAP3 associates with focal adhesions 
and regulates stress fibers [397]. ASAP1 has been suggested to be an important 
regulator of cellular structures, like FAs, CDRs, Invadopodia, and podosomes [398, 
399], thus it is important for FA turnover, receptor recycling, cell migration, cell 
spreading and tumor invasion [396]. ASAP1 and 2 were recently found present in 
platelets using a proteomic approach [352].  
ARAP subfamily 
ARAPs consist of the most complex of domains compared to other ArfGAPs, including 
ArfGAP, RhoGAP, ankyrin repeats, and Ras association domains. The domain structure 
of ARAPs indicates that they are important coordinators of two or more GTPase 
signaling pathways. There are three members of this subfamily in humans, and they 
are distinct in functions and cellular locations with different Arf, Rho, and Ras binding 
specificity for individual ARAPs. ARAP1 uses Arf1 and Arf5 as substrates [400]. ARAP2 
uses Arf6 preferentially as compared with Arf1 and Arf5 in vitro and in vivo [401, 402]. 
ARAP3 has been reported to function as an Arf6 or Arf5 GAP in vitro [403, 404] and to 
regulate Arf6-dependent event including membrane protrusions and ruffling in vivo 
[403, 405]. PI(3,4,5)P3 could stimulate the Arf GAP activity of ARAPs [406, 407]. ARAPs 
affect EGFR-mediated signaling, FA dynamics, lamellipodia formation [396, 408] and 
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recently integrin α5β1 trafficking [402]. ARAP1 was also found in the platelet 
proteomics study [352].  
ACAP subfamily 
ACAP is an acronym for ArfGAP with coiled-coil (identified as a BAR domain later), 
ankyrin repeat, and PH domain [396]. ACAP1 and 2 have a preference for Arf6 over 
other Arfs in vitro and in vivo, and PI(4,5)P2 and PA are important lipid components 
for their ArfGAP activity [409]. ACAPs are reported to regulate Arf6-dependent actin 
remodeling and endocytosis and receptor tyrosine kinase-dependent cell movement. 
ACAP1, as an effector of Arf6, functions as part of a clathrin coat complex, mediating 
the stimulation-dependent endocytic recycling of integrin and glucose transporter 
type 4 [410]. Thus, it is important for cell migration and glucose homeostasis. Also, 
overexpression of ACAP1 in Hela cells reduces FAs formation [411]. ACAP2 regulates 
neurite outgrowth by linking the two small GTPases, Rab35 and Arf6 [412]. ACAP1 and 
2 were also found in the platelet proteomics study [352]. 
Arf6 Regulation and its Role In platelets 
Although Arf6 was first identified in 1991 [413], the first study of roles of Arf6 in 
platelets occurred actually 15 years later by Choi et al. from our group [414]. Before 
our studies, it had been projected that Arf proteins may play some role in the αIIbβ3 
integrin signaling [399, 415]. Oda and colleagues found that ASAP1, an ArfGAP protein, 
is present in platelets and can be recruited to peripheral focal adhesions via CrkL, a 
SH2 and SH3 adapter for WASP, syk and STAT5 in platelets [415, 416], suggesting a 
potential role for Arf in platelets. Our previous work, by Choi and Karim, showed that 
in resting platelets, Arf6 is present in the GTP-bound form, and upon platelet 
activation, Arf6-GTP is quickly converted to Arf6-GDP. This transition is regulated by 
two waves of platelet signaling pathways, primary signaling (e.g. PAR receptor, GPVI) 
and contact-dependent signaling (e.g. αIIbβ3 integrin) [417]. Blocking integrin αIIbβ3 
outside-in signaling could partially reverse the loss of Arf6-GTP, suggesting a 
regulation of Arf6 by signaling downstream of integrin αIIbβ3. It was shown that Arf6 
is downstream of many well-known platelet signaling steps, like PLC, PI3K, PKC, and 
Syk. Using an inhibitory, myristoylated Arf6 N-terminal peptide, loss of Arf6-GTP could 
be blocked, probably due to the inhibition of the Arf6 GAP activity by the peptide. 
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Pretreatment with this peptide inhibited platelet aggregation, adhesion and spreading 
on collagen-coated surface, and activation of Rho family members, suggesting the 
central role of Arf6 in platelet activation.  
Recently, Arf6 was suggested to be involved in P2Y receptor endocytosis [54] and in 
dense granule secretion, but not α-granule or lysosome secretion [353] in platelets. It 
was shown that P2Y activation by ADP could stimulate Arf6 activation, and activated 
Arf6 stimulates Nm23-H1, a nucleoside diphosphate kinase, which in turn promotes 
dynamin-dependent internalization of P2Y receptors. It was also proposed that Arf6-
GTP in resting platelets is maintained by cytohesin-2, an ArfGEF protein, and upon 
platelet activation, PKC-mediated phosphorylation of cytohesin-2 decreases the 
interaction between Arf6-GTP and cytohesin-2, leading to loss of Arf6-GTP and platelet 
secretion. However, it should be noted that these studies used Myr-Arf6 peptide and 
pharmacological inhibitors, and the dynamics of Arf6-GTP changes were not 
consistent with previous reports. Thus there is confusion over the role of Arf6 in 
platelets justifying the need for more experimental data and better systems to 
evaluate Arf6 function. Using conditional knockout mice as done in this dissertation 
may shed light on the role of Arf6 in platelet function and hemostasis. 
 
Subsection Four: G Protein-coupled Receptor Kinase Interacting Protein (GIT) 
GIT Family 
GITs were originally identified as G protein-coupled receptor kinase interacting 
proteins. There are two members in this family, GIT1 and GIT2. GIT1 expression is 
prominent in endothelial cells, while GIT2 is almost ubiquitous [418]. They consist of 
N-terminal ArfGAP domain, three Ankyrin (ANK) repeats, a Spa-homology domain 
(SHD), a coiled-coil domain and a C-terminal paxillin-binding site (PBS). Through 
interactions with various proteins, GITs could form a big complex regulating 
membrane traffic and actin cytoskeleton-related structures, like FAs. GITs exhibit 
efficient and almost equivalent GAP activity toward Arf1 and Arf6 in vitro [419-421] 
and GITs prefers Arf6 as substrate which is supported by the colocalization of GITs 
with Arf6 in the cell periphery in vivo [422-424]. GITs are present in platelets shown 
by western blot [425] and by proteomic approach [352]. However, its role in platelet 
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is unknown, although it was suggested to be involved in integrin αIIbβ3 downstream 
signaling.  
GIT Domains and Corresponding Interacting Partners 
The ArfGAP domain 
Like other ArfGAP proteins, GITs contain a zinc-finger-like motif essential for their GAP 
activity [368, 426]. GITs’ ArfGAP domain could function on both Arf1 and Arf6 [419] 
and the ArfGAP activity could be stimulated by PI(3,4,5)P3 but not by PI5P, PI(4,5)P2 
or diacylglycerol (DAG) [422]. A truncated GIT mutant lacking the ArfGAP domain, or 
ArfGAP activity deficient mutant (R39K) resulted in the formation of very large GIT1-
containing recycling endosomes [427-429], suggesting that ArfGAP activity is 
necessary to maintain proper membrane trafficking.  
The ANK repeats 
ANK repeats usually mediate protein-protein interaction and have diverse binding 
partners. For GIT2, there is a potential paxillin binding site between the ANK repeat 
and the SHD domain, although this is not the dominant binding site for paxillin [430]. 
Truncated GITs mutant consisting of only the ArfGAP and the first ANK repeat localizes 
to endosome, and further depletion of the first ANK repeat results in diffused 
cytoplasmic distribution of the ArfGAP domain [427, 429], suggesting the first ANK 
repeat may regulate the binding of GITs to endosome.  
The SHD domain 
The SHD domain is an important binding site mediating formation of a large oligomeric 
complex. There are multiple binding partners for this domain, including p21-activated 
kinase interacting exchange factor (PIX), PLCγ and MEK1.  
PIX is a Dbl-homology and pleckstrin-homology (DH/PH) domain-containing protein, 
and thus can serve as a GEF for Rac1 and Cdc42 [431-433]. PIX binds to GIT via its α-
helical region of the C-terminus. GIT and PIX could form large aggregates in the cell 
[434, 435], consistent with the fact that both proteins can homodimerize. Disrupting 
their interaction causes diffuse cytoplasmic localization of both proteins [432, 436]. 
Through PIX, GITs can also interact with p21-activated kinase (PAK). PAK interacts 
directly with PIX and is thus recruited to GIT-PIX oligomers [427, 437, 438]. It was 
suggested that in response to extracellular stimuli, activated Rac1/Cdc42 induces a 
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conformational change in PAK which allows association of Rac1/Cdc42-PAK with GIT-
PIX oligomers [438]. Local accumulation of PAK at GIT-PIX complex induces its 
autophosphorylation and subsequent activation of PAK [432]. PAK recruitment to GIT-
PIX oligomers mediates translocation of this complex to focal complexes, and through 
unknown mechanism that requires ArfGAP activity, Rac1 is inactivated in a GIT-
dependent manner [439, 440], providing a negative feedback regulation.  
GIT1, via its SHD domain, binds to a PLCγ SH2 domain but does not bind to PLCδ and 
PLCβ [441, 442]. Knocking down GIT1 expression inhibits agonist-mediated PLCγ 
phosphorylation and Ca2+ release [441].  
MEK1 is another interacting partner of GIT1 that binds the SHD domain [443] and is 
an upstream kinase for ERK1/2. Through MEK1, GIT1 may spatially regulate ERK1/2 
activation. Overexpression of GIT1 prolongs ERK1/2 activation in response to 
epidermal growth factor (EGF) stimulation, and knocking down GIT1 inhibits EGF-
mediated activation of ERK1/2 [443]. It has been shown that GIT1-mediated c-Src-
dependent activation of Erk1/2 plays various roles in regulating focal adhesion and cell 
migration in vascular smooth muscle cells and Hela cells [443, 444]. 
The coiled-coiled domain 
The coiled-coil domain resides between the SHD and the PBS, and mediates GIT1 and 
GIT2 homo- and hetero-dimerization [435, 445].   
The PBS binding site 
Paxillin is a focal adhesion adaptor protein containing five leucine-rich domains (LDs) 
and four C-terminal LIM domains. GIT1 and GIT2 bind to the LD4 region of paxillin 
through their PBS [427, 428, 438, 446]. In addition to that, LDs also mediates paxillin 
binding to vinvulin, FAK and integrin, tyrosine phosphorylated motifs that mediate 
binding to SH2 domains and proline-rich motifs that mediate binding to SH3 domains 
[447]. Through paxillin, GITs localize to focal complexes, and depletion of either the 
GIT PBS region or the paxillin LD4 motif prevents GITs from associating with focal 
complexes [428, 438, 440]. It has been proposed that association of PAK with GIT-PIX 
actually helps unmask the PBS region for paxillin binding and subsequent recruitment 
of GIT-PIX complex to focal complex. This model is supported by several lines of 




GITs have multiple phosphorylation sites and it appears that phosphorylation of 
certain residues is important for GIT activity. The kinases known to mediate GIT 
phosphorylation include Src, FAK and protein kinase D3 (PKD3) [437, 443, 449, 450]. It 
has been shown that tyrosine phosphorylation of GIT1 at residue 392 is important for 
activation of PLCγ and podosome formation in vascular smooth muscle cells [451]. 
PKD3 was shown to directly phosphorylate GIT1 on serine 46, regulating its subcellular 
localization and cellular protrusive activity [450]. The only phosphatase regulating the 
dephosphorylation of GITs is protein tyrosine phosphatase ζ (PTPζ) [449].  
GIT1 in Membrane Ttraffic 
GIT1, via its GAP activity to Arf6, affects ligand-stimulated endocytosis of several 
GPCRs through either clathrin-dependent or clathrin-independent endocytic 
pathways [452]. Overexpression of GIT1 and GIT2 disrupts the internalization of some 
agonist-bound receptors from the plasma membrane, including the β1- and β2-
adrenergic, adenosine 2B, µ-opioid, M1 muscarinic and EGF receptors [419, 420, 453]. 
GIT mutations affecting the ArfGAP domain diminish the effect of overexpressed GITs 
on receptor internalization [419].  
GITs also regulate presynaptic and postsynaptic vesicle trafficking. Through the 
presynaptic proteins piccolo and scribble, GIT1 participates in organization and release 
of presynaptic vesicles [445, 454]. Moreover, interaction of GIT1 with liprin-α, a 
postsynaptic protein, anchors AMPA glutamate receptors to post-synaptic densities. 
GIT1 was also found to regulate synaptic vesicle recycling by direct association with 
the endocytic adaptor stonin2, linking the endocytic machinery to the cytomatrix at 
the active zone [455]. 
GITs may affect membrane trafficking at other points in the endocytic pathway. Point 
mutants that lack GAP activity and truncation mutants that lack the Arf GAP domain 
induce a membrane-delimited structure containing transferrin, paxillin and Rab11 
[283, 428]. However, the physiologic function of this compartment is not yet 
determined.  
GIT1 in Cytoskeleton Rearrangement 
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GITs’ role in cytoskeleton rearrangement is mainly through their interacting partners 
during cell spreading and migration. It has been proposed that the GIT-containing 
complexes mediate the coordinated movement of actin regulators between sites of 
activity. It seems that a GIT-containing complex, consisting of paxillin, PAK and PIX, 
cycle among three intracellular sites: the cell edge, FAs and punctate cytoplasmic 
structures [456]. GIT, through its PBS, associates with the adhesive structures and the 
cell edge and interacts with paxillin; while, via its SHD domain, GIT associates with the 
cytoplasmic structures [423, 424, 456]. Given that the cytoplasmic structures are not 
associated with any membrane compartment markers, they are thought to be 
supramolecular complexes but not vesicles. This cytoplasmic structure could be the 
mediator regulating the movement of actin regulator proteins between FAs and the 
cell edge [456]. Overexpression of mutant GIT or interacting partners that prevent 
their association affect the function of GIT on actin remodeling and cell movement. 
For example, overexpression of the isolated PBS or the isolated N-terminus of GIT 
prevents association of PIX and PAK with FAs [456]. Expression of paxillin that does 
not bind GITs or a GIT2 mutant lacking PBS resulted in increased random motility, 
decreased directed motility, and formation of broad lamellipodia [440, 457], 
suggesting GITs play an important role in proper directionality of cell movement. This 
direction-determined function of GIT1 is also shown in endothelial cells during 
pathological angiogenesis by interacting with cortacin, a protein critical for directional 
migration [458]. It seems that the interaction between βPIX and MYO18 is important 
for focal adhesion turnover and cell migration [459]. GIT1 is also important for the 
formation of podosomes, actin-rich structures important for cell migration [460].  
By modulating the F-actin cytoskeleton, the GIT1-βPIX-Rac1-PAK complex recently has 
been shown to play a crucial role in maintaining the stability of GABAA receptors, an 
essential mediator of inhibitory neurotransmission in central nervous system [461].  
GIT1 in Other Functions 
In endothelial cells, Robo4 (Roundabout homolog 4) interacts with paxillin, which 
recruits GIT1 to inactivate Arf6, causing vascular stability, blocking cellular protrusions 
and neovascular leak [462]. In the same cells, GIT1 is proposed to regulate NO 
production by interacting with endothelial nitric-oxide synthase [463]. In epithelial 
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cells, GIT1 is proposed to suppress EphA2 (Erythropoietin-producing hepatocellular 
carcinoma)-mediated Arf6 activity, which provides a positive feedback loop to 
enhance E-cadherin-based cell-cell contacts [464]. GIT1 is also identified as a novel 
regulator of vascular smooth muscle cell proliferation, migration, and apoptosis 
through PLCγ and Erk1/2 signaling pathways, and thus is important for vascular 
remodeling [465]. In breast cancer cells, GIT1 may enhance tumor cell invasion and 
metastasis by preventing paxillin and α5β1 integrin from degradation and thus 
enhancing α5β1 integrin-mediated cell adhesion to fibronectin and collagen [466].  
GIT1’s Physiological Roles 
Given the effect of GIT1 in brain function, it is not surprising that GIT1 knockout mice 
are defective in fear learning [467] and dendritic spine formation [468]. GIT1 deficient 
mice also exhibited delayed fracture healing, resulting from reduced bone formation 
[468], and decreased secretion of VEGF, which is probably due to impaired BMP2 
signaling [469]. GIT1 also regulates mitochondrial biogenesis in heart and global GIT1 
knockout mice exhibit enhanced cardiomyocyte apoptosis and cardiac dysfunction, 
probably due to abnormal mitochondria function in heart [470]. Attention-deficit 
hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in 
children. It has been shown that an intronic single nucleotide polymorphism in GIT1, 
which could cause reduced GIT1 expression, is associated with ADHD susceptibility in 
humans [471]. This cause-effect relation is supported by the observations in GIT1-
deficient mice [471]. However, in a study of Brazilian children, GIT1 s (SNPs) are not 
associated with ADHD [472]. Further data will be needed to valid that. GIT1 was also 
demonstrated to participate in vascular pulmonary vascular development by 
regulating VEGF-mediated PLCγ and ERK1/2 activation [473]. Due to that, global GIT1 
knockout mice has markedly reduced numbers of pulmonary blood vessels and 
increased alveolar spaces.  
In summary, GIT1 plays important roles in the functions of multiple systems. It is not 
surprising that global GIT1 knockout mice exhibited ~60% perinatal mortality [473].  
Summary 
Platelets are important players in thrombosis, hemostasis and beyond. Our previous 
work has shown that Arf6 is tightly regulated in platelets and is important for platelet 
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activation (e.g. platelet adhesion, spreading, and aggregation) [414, 417]. However, it 
is still unclear what Arf6 does in platelets and how Arf6 achieves it?  
An interesting phenomenon to Arf6 in platelets is that resting platelets maintain 
relatively high level of Arf6-GTP which goes down rapidly upon platelet stimulation. 
We have proposed that Arf6-GTP could help platelets keep in the resting state by 
cycling membrane protein (e.g. integrins) and preventing cell-cell or cell-matrix 
contact. Conversely, Arf6-GDP allows platelets to interact with each other or with 
matrix, for full platelet activation. Interestingly, most platelet receptors are implicated 
to actively cycle between endosomes and the plasma membrane. A well-studied one 
is integrin αIIbβ3 which is likely to cycle between the plasma membrane, α-granules, 
and dense-granules. Upon platelet stimulation, intracellular pools of integrin αIIbβ3 
are exposed on the plasma membrane and, together with surface pools, mediate 
platelet aggregation. Recent findings suggested in platelets that Arf6 mediated P2Y 
receptor endocytosis and regulated dense-granule exocytosis. However, the 
molecular mechanism involved in these processes makes the role of Arf6 controversy. 
One shows that Arf6 is in GDP state in resting platelets; the other shows that Arf6-GTP 
level in resting platelets is sequestered by its regulator. Therefore, it becomes needed 
to have a better system and more experimental data to uncover the role of Arf6 in 
platelets. In the first part of this thesis, platelet-specific, Arf6 knockout mice were 
generated to explore the role of Arf6 in platelets.  
Another interesting phenomenon in our previous findings is that the Arf6-GTP level is 
partially recovered by inhibiting integrin αIIbβ3 outside-in signaling and platelet 
aggregation. This raises an important question: how is Arf6 regulated in platelets? The 
observation can be simply explained by a scene in which an Arf6 GAP protein is 
activated following integrin αIIbβ3 outside-in signaling. Of course, other explanations 
are equally possible. Therefore, identifying the regulators, GEFs or GAPs, in platelets 
would help better understand the role of Arf6. Proteomics studies have shown the 
presence of multiple Arf6 regulators in platelets. During the preliminary search, GIT1, 
a GAP protein, stood out. GIT1 is a multi-domain protein, containing a C-terminal PBD 
which allows the association of GIT1 to integrin via paxillin. GIT1 tyrosine 
phosphorylation is regulated by integrin outside-in signaling. The second part of this 
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Chapter Two: Reagents and Methods 
Reagents and Antibodies 
Custom Myr-Arf1/Arf6 peptide (residue 2-13 of its N-terminal), scrambled Myr-Arf6 
peptide (scArf6, Myr-FINGLEVKKFSK) and RGDS peptide were from Anaspec (San Jose, 
CA). Apyrase, human fibrinogen, cytochalasin D, tetramethyl rhodamine 
isothiocyanate (TRITC)-phalloidin, poly-D-lysine, glutathione-agarose, hirudin and 
proteinase K were from Sigma (St. Louis, MO). latrunculin A was from Calbiochem (San 
Diego, CA). Thrombin, Collagen, ADP, and CHRONO-LUME reagent were from Chrono-
log (Havertown, PA). U46619 and prostaglandin I2 (PGI2) was from Cayman (Ann Arbor, 
MI). A23187 was from Calbiochem (San Diego, CA). Convulxin was from Centerchem 
(Norwark, CT). PAR1/PAR4-peptide was from Bachem (Bubendorf, Switzerland). 
Fibronectin-free fibrinogen was from Enzyme Research Laboratory (South Bend, IN). 
DNA ligation Kit was from Enzymax (Lexington, KY). Fura-2/acetoxymethyl ester (AM) 
was from Molecular Probes (Eugene, OR). Complete, EDTA-free protease inhibitor 
cocktail was from Roche (Indianapolis, IL). Acid citrate dextrose (ACD) blood collection 
tubes were from BD diagnostics (Sparks, MD). 70% glutaraldehyde was from Electron 
Microscopy Sciences (Hatfield, PA). Other reagents used were at least laboratory 
grade.  
Rabbit anti-GIT1 antibody was from Bethyl Laboratory (Montgomery, TX). Mouse 
monoclonal antibodies against protein GIT1, Hic-5, Rac1, Cdc42, and FITC-anti-CD62P 
antibody and PE-anti-LAMP1 antibody were from BD Biosciences (San Jose, CA). 
Mouse anti-RhoA antibody was from Cytoskeleton (Denver, CO). Rabbit anti-GIT1 
antibody and rabbit anti-phospho-myosin light chain antibody were from Santa Cruz 
(Dalla, TX). Rabbit anti-β-PIX antibody and rabbit anti-Integrin β3 antibody were from 
Cell Signaling (Danvers, MA). Rabbit anti-Arf1/3 antibody, rabbit anti-Sema3F antibody 
and mouse anti-actin antibody were from Sigma (St. Louis, MO). Mouse anti-p-selectin 
antibody, rabbit anti-VMAT2 antibody, rabbit anti-vWF antibody and mouse anti-
fibronectin antibody were from Abcam (Cambrige, MA). FITC-anti-CD41/CD61 
antibody and PE-Jon/A antibody were from Emfret Analytics (Eibelstadt, Germany). 
Rabbit anti-fibrinogen antibody was from Dako (Glostrup, Denmark). Rabbit anti-
vitronectin antibody was from Molecular Innovation (Novi, MI). Rabbit anti-murine 
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PF4 antibody was from R&D Systems (Pittsburgh, PA). Mouse anti-phospho-tyrosine 
antibody (4G10 clone platinum) and anti-FAK antibody were from Millipore 
(Darmstadt, Germany). Rabbit Anti-Arf6 serum was homemade as described before 
[414]. Rabbit anti-RabGDI polyclonal antibody was generated by Dr. Tara Rutledge in 
our laboratory using recombinant RabGDIα as antigen.  
Generation of Arf6flox/flox/PF4-Cre+ Mice (Arf6 KO Mice) 
All animal procedures were done under and approved protocol (884M2005) from the 
University of Kentucky Institutional Animal Care and Use Committee (IACUC) 
Embryos of Arf6flox/flox mouse [474] were a generous gift from Dr. Kanaho (University 
of Tsukuba, Tsukuda, Japan) and were recovered under contract with the Jackson 
laboratory (Bar Harbor, ME). The animals were crossed with a PF4-Cre+ strain [475] 
which was a generous gift from Dr. Radek Skoda, (University Hospital Basel, 
Switzerland). Polymerase Chain Reaction (PCR)-based genotyping was performed 
using genomic DNA isolated from tail tip of individual mouse. For Arf6 gene, the PCR 
analysis was carried out using following primer set:  
forward primer, 5’-GACCCCATGAGTGTTGTCAC-3’, 
reverse primer, 5’-GGGATACATAGAGAAACCTTGTCTCAGG-3’. 
The PCR yields a 240 bp DNA product for WT allele and a 270 bp one for floxed allele. 
The PCR analysis for the Cre transgene was carried out using the following primer set:  
for the wild type allele,  
forward primer 5’-CCCATACAGCACACCTTTTG-3’, 
reverse primer 5’-GAAACAACAGGCCCAGAAGC-3’;  
for the Cre allele,  
forward primer 5’-CCCATACAGCACACCTTTTG-3’, 
reverse primer 5’-TGCACAGTCAGCAGGTT-3’.  
PCR yielding a 450 bp DNA product indicates the presence of PF4-Cre gene.  
PCR conditions for both Arf6 gene and PF4-Cre gene are: 94°C for 10 min for 1 cycle, 
followed by 30 cycles of 94°C for 1 min, 54°C for 45 sec and 68°C for 30 sec, and lastly 
68°C for 7 min for 1 cycle. 
Platelet specific Arf6 KO mice (Arf6flox/flox/PF4-Cre+) were generated by crossing two 
above murine strains. WT littermates (Arf6flox/flox/PF4-Cre-) were used as control. 
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Generation of GIT1flox/flox/PF4-Cre+ Mice (GIT1 KO Mice) 
GIT1flox/flox mice [467] were a generous gift from Dr. Premont (Duke University). PCR 
analysis was carried out using the following primer set:  
forward primer: 5’-CCCAGAATGTCAAGCTGGTT-3’, 
reverse primer: 5’-GATCAGCCACCTCTGCCAAG-3’. 
Using same PCR conditions for Arf6 gene, WT allele gives a 360 bp DNA product and 
floxed allele gives a 380 bp DNA product. PCR products were determined by DNA 
agarose (containing Ethidium Bromide) electrophoresis.  
Platelet specific GIT1 KO mice (GIT1flox/flox/PF4-Cre+) were generated by crossing 
GIT1flox/flox/PF4-Cre- mice with GIT1flox/flox/PF4-Cre+ mice. WT littermates 
(GIT1flox/flox/PF4-Cre-) were used as control. 
Generation of Integrin β3 KO Mice 
Integrin β3 KO mice [476] were a generous gift from Dr. Zhenyu Li (University of 
Kentucky). PCR analysis was carried out using the following primer set: 
forward primer: 5’-CTTAGACACCTGCTACGGGC-3’, 
reverse WT:  5’-CCTGCCTGAGGCTGAGTG-3’, 
reverse Neo: 5’-CACGAGACTAGTGAGACGTG-3’. 
Using same PCR conditions for Arf6 gene, WT allele give a 446 bp DNA product and 
neo allele gives a 538 bp DNA product. 
Genomic DNA Isolation from Mouse Tail Tip  
Mouse tail tips (3-5 mm) were digested overnight (O/N) at 55°C in 400 µl tail lysis 
buffer (50 µM Tris/HCl, pH 7.5, 100 µM EDTA, 100 µM NaCl, and 1% SDS after 
autoclave) containing 20 µl 10 mg/ml proteinase K., Protein/peptide was precipitated 
by mixing with 200 µl saturated 6 M NaCl and centrifuged at 13,000 x g for 30 min at 
room temperature (RT). The supernatant containing DNA was harvested and mixed 
with equal volume of 100% ethanol. After incubation for 10 min at RT, DNA was pellet 
down by centrifuge at 13,000 x g for 10 min. DNA pellets were washed once with 1 ml 
70% ethanol and then dried in a vacuum centrifuge for around 20 min. Genomic DNA 
was finally dissolved in 100 µl autoclaved ddH2O.  
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Whole Blood Count 
Animals were euthanatized by CO2 asphyxiation just prior to harvest blood. Using 
sodium citrate as anticoagulant, mouse blood was harvest via heart puncture by 26G 
needles attached to a syringe which contains 100 µl mixture of 3.8% sodium citrate, 2 
U/ml apyrase and 100 ng/ml PGI2. Whole blood counting was performed using 
Hemavet (DREW Scientific, Erba Diagnostics, Inc.). Concentrations of blood cells (red 
blood cells, white blood cells, and platelets) were determined by back-calculation 
according to anticoagulant dilution factor. Also, the platelet size was recorded. 
Analysis of both blood count and platelet size was performed using Sigmaplot 12.0 
(Systat software Inc.). 
Preparation of Mouse Platelets 
Animals were euthanatized by CO2 asphyxiation just prior to harvest blood. Using 
sodium citrate as anticoagulant, mouse blood was harvest via heart puncture with a 
26G needle attached to a syringe which contains 100 µl mixture of 3.8% sodium citrate, 
2 U/ml apyrase and 100 ng/ml PGI2. Blood was diluted in HEPES Tyrode buffer (pH 6.5, 
20 mM HEPES/KOH, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 5 mM D-glucose, 12 mM 
NaHCO3, 0.4 mM NaH2PO4) in 1:1 ratio in the presence of 0.2 U/ml apyrase and 10 
ng/ml PGI2 and then pooled in a 15 ml conical tube. Whole blood was subjected to 
centrifugation at 215 x g for 10 min at RT and the supernatant (platelet rich plasma, 
PRP) was recovered. To remove residual red blood cells and white blood cells, PRP was 
subjected to centrifugation again at 215 x g for 10 min at RT. To recover the platelets, 
the PRP was subjected to centrifugation at 675 x g for 10 min at RT. Platelet pellet was 
resuspended in HEPES Tyrode buffer (pH 6.5) containing 0.2 U/mL apyrase, 10 ng/mL 
PGI2 and 1 mM EGTA. After a second centrifugation step at 675 x g for 10 min at RT, 
platelet pellets were resuspended in HEPES Tyrode buffer (pH 7.4) supplemented with 
1 mM CaCl2. Platelet concentration was measured using Z2 Counter (Beckman Coulter, 
Inc., Miami, FL) and adjusted with HEPES Tyrode buffer (pH 7.4) to the concentrations 
indicated. Platelets were incubated at RT for 30 min before use. 
Preparation of Fresh Human Platelets 
Fresh whole blood was drawn from informed healthy donor using acid citrate dextrose 
(ACD) collection tubes (BD Biosciences). Whole blood was diluted in HEPES Tyrode 
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buffer (pH 6.5) with 1:1 ratio in the presence of 0.2 U/ml apyrase and 10 ng/ml PGI2. 
After centrifugation at 215 x g for 20 min at RT, the supernatant (PRP) was harvested. 
To remove residual red blood cells and white blood cells, PRP was subjected to 
centrifugation at 155 x g for 10 min at RT. Platelets were recovered from the resulting 
PRP by centrifugation at 750 x g for 13 min at RT, and then resuspended in HEPES 
Tyrode buffer (pH 6.5) in the presence of 0.2 U/ml apyrase, 10 ng/ml PGI2 and 1 mM 
EGTA. Platelets suspensions were subjected to centrifugation again at 750 x g for 13 
min at RT and the resulting pellet was resuspended in HEPES Tyrode Buffer (pH 7.4) 
supplemented with 1 mM CaCl2. Platelet concentrations were determined by using Z2 
Counter (Beckman Coulter, Inc., Miami, FL) and adjusted to 4 X 108/ml with HEPES 
Tyrode buffer (pH 7.4), unless otherwise indicated. Platelets were incubated at RT for 
30 min before use. 
Preparation of Banked Human Platelets 
Human platelet rich plasma (PRP) was obtained from the Kentucky Blood Center. The 
PRP was pooled in a 50 ml conical tube and pre-incubated with 0.2 U/ml apyrase and 
10 ng/ml PGI2 for 10 min. To remove residual red blood cells (RBC) and white blood 
cells (WBC), PRP was subjected to centrifugation at 155 x g for 13 min at RT. After this 
step, the platelets were treated as described in the previous “preparation of fresh 
human platelets” section. 
Platelet Aggregometry and ATP Release Measurements 
Washed platelets were freshly prepared and adjusted to the desired concentration 
with HEPES Tyrode buffer (pH 7.4) containing 1 mM CaCl2. Platelets suspensions (250 
or 500 µl) in a siliconized glass cuvette (Chrono-log, Havertown, PA) was warmed to 
37°C under stirring conditions (1200 rpm) for 2-3 min in a Model 460Vs Lumi-dual 
aggregometer (Chrono-log). After pretreatment with the indicated reagents, platelets 
were stimulated with the indicated agonists to initiate platelet aggregation. A model 
810 Aggro/Link computer interface and Aggro/Link software (Chrono-log) were used 
to monitor platelet aggregation traces. Buffer alone had been used to set baselines. 
ATP release from platelets dense-core granules was monitored using CHRONO-LUME 
reagents (Chrono-log) while measuring platelet aggregation. CHRONO-LUME reagents 
containing luciferin and luciferase were pre-incubated with platelet suspension (1 to 
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20 ratio) for 1 min prior to addition of agonists. Luminescence traces were recorded 
using the same interface and software as platelet aggregation. Graphs of platelet 
aggregation and ATP release was processed and assembled into figures using Adobe 
Photoshop CS5 (Adobe Inc. San Jose, CA). 
Flow Cytometry Analysis 
Washed platelets from WT and KO mice were freshly prepared and adjusted to 5 X 
107/ml in HEPES Tyrode buffer (pH 7.4) in the presence of 1 mM CaCl2. Platelets (20 µl) 
were either kept resting or stimulated with 0.1 U/ml thrombin for 1 min. The reactions 
were stopped by adding a 2 fold excess of hirudin. Samples were then incubated with 
fluorophore-conjugated antibodies (2.5 µl each) for 15 min at RT. FITC-anti-
CD41/CD61 antibody, PE-Jon/A antibody, FITC-anti-CD62 antibody and PE-anti-LAMP1 
antibody were used to measure surface levels of total integrin αIIbβ3, active integrin 
αIIbβ3, P-selectin, and LAMP1, respectively. The mixture was transferred to 
polystyrene FalconTM tubes (BD Biosciences, San Jose, CA) containing 200 µl HEPES 
Tyrode buffer (pH 6.5). Unlabeled platelets were used as background controls. 
Samples were analyzed at the flow cytometry facility at University of Kentucky. Flow 
cytometry analysis was performed using FACScanTM flow cytometer (BD Biosciences). 
Platelet populations were determined by combination of forward light scattering (FSC) 
and side light scattering (SSC). CellQuestTM (BD Biosciences) was used to monitor 
platelet fluorescent intensities. A total of 10,000 platelet events were analyzed and 
the geometric mean of the fluorescent intensity were determined and analyzed using 
the SigmaPlot 12.0 statistical routines.  
Electron Microscopy 
Washed platelets from WT and KO mouse were prepared and adjusted to 4 X 108/ml. 
Platelets (500 µl) were either kept resting or stimulated with 0.1 U/ml thrombin for 3 
min, followed by fixation using equal volume of 0.1% glutaraldehyde in White’s Saline 
[solution A (20X, 2.4 M NaCl, 0.1 M KCl, 46 mM MgSO4.7H2O, 64 mM Ca(NO3).H2O), 
solution B (20X , 130 mM NaHCO3, 8.4 mM Na2HPO4 , 3.8 mM KH2PO4 , 0.01% Phenol 
Red]. After fixation in a 37°C metal block for 15 min, platelets were subjected to 
centrifugation at low speed (3000 x g) for 2 min. Platelet pellet were resuspended in 
cold 3% glutaraldehyde in White’s saline, followed by incubation at 4°C for 1 h. After 
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3X washing with White’s saline, platelet pellets were recovered by centrifugation at 
maximum speed (13,000 x g) and then resuspended in 300 µl 1% OsO4 (osmium 
tetroxide, to make 4.5 ml add 2.25 ml OsO4, 225 μl White’s A, 225 μl White’s B, 2 ml 
ddH2O) for 30~60 min on ice. The pellets are then washed three times with 1 ml 
White’s saline, followed by another two washes with 1 ml ddH2O. The samples were 
dehydrated with a series of ethanol washes (50%, 70%, 90%, 100% absolute ethanol), 
5 min each, followed by two washes with propylene oxide. The samples were 
infiltrated with 1 ml of 1:1 propylene oxide: Spurr’s resin (18 g VCD/ERL 4221, 14 g 
DER, 48 g NSA, well mixed with a wooden spatula without generating air bubbles; add 
0.6 g DMAE and mix by stir for 20 min) and incubated overnight on a rotator at RT. The 
platelets were recovered by centrifugation and the platelet pellet was resuspend in 
new Spurr’s resin followed by incubation on rotator for 1 hr at RT. This was repeated 
4-5 times. Finally the samples were embedded in Spurr’s resin (~200 μl volume) and 
allowed to polymerize for 48 hr at 60°C. Polymerized blocks were sectioned using a 
Reichert-Jung Ultracut E. microtome and mounted onto copper grids. Following 
counterstaining with uranyl acetate and lead citrate (if necessary for contrast), sample 
grids were viewed on a Hitachi H-7000 transmission electron microscope and images 
were obtained with Gatan digital micrograph software (Pleasanton, CA). 
Platelet Adhesion 
Washed platelets from WT and KO mice were freshly prepared and adjusted to 5 X 
108/ml in HEPES Tyrode buffer (pH 7.4). Washed platelets were then incubated for 30 
min at 37°C with 7 µM calcein AM (BD Bioscience) in the presence of 0.2% of pluronic 
F-127 (Invitrogen). After centrifugation, platelets were resuspended in double the 
original volume of HEPES Tyrode buffer (pH 7.4, the platelet final concentration is 2.5 
X 108/ml) in the presence of 1 mM Ca2+. 50 µl labeled platelets were then seeded on 
96-well opaque plate which was pre-coated with either 50 µg/ml human fibrinogen or 
5% BSA (background control) in Tris buffer (25 mM Tris, 137 mM NaCl, pH 7.4). After 
incubation for 30 min at 37°C, the plates were washed twice with HEPES Tyrode Buffer 
(pH 7.4) and adherent platelets were measured using a fluorescence plate reader 
(SpectraMax M5, Molecular Devices, Sunnyvale, CA) with excitation/emission/cutoff 
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at 485/538/515, respectively. Standard curves, to calculate cell binding, were 
generated using platelets of serial fixed numbers from each genotype.  
Platelet Spreading 
Fibrinogen-coated slides were prepared by incubating 50 µg/ml human fibrinogen 
(Enzyme Research Laboratory) in PBS onto Nunc Lab-Tek II 16 well chamber slide 
(Thermo Scientific) overnight at 4°C. Washed platelets (2 X 107/ml) were prepared 
from mouse blood and resuspended in HEPES Tyrode buffer (pH 7.4) containing 1 mM 
CaCl2. Before seeding on fibrinogen-coated slide, washed platelet suspensions (100 µl) 
were supplemented with 1 µl platelet-poor plasma (PPP). The slides were incubated 
at 37°C for the indicated times. The unbound platelets were removed by washing and 
the adherent platelets were fixed with 4% paraformaldehyde overnight at 4°C.  
For TRITC-phalloidin staining, platelets were permeabilized with permeabilization 
buffer (0.1 M Tris, 0.1% Triton X-100, 0.15 M NaCl, 0.01 M EGTA, 5 mM, MgCl2, pH 7.4) 
for 30 min at Room Temperature (RT). After washing with PBS, platelets were stained 
with 0.1 µM TRITC-phalloidin (Sigma, St Louis, MO) in permeabilization buffer for 30 
min at RT. After 3 washes with 1X PBS, platelets were mounted with VectorShield 
preservative (Vector Laboratories) on a Lab-Tek coverglass. Coverglasses were sealed 
with nail polish and samples were visualized immediately or kept at 4°C prior to image 
processing. Images were visualized using Nikon Eclipse E600 microscope (Nikon, 
Melville, NY) with a 100X/1.40 numeric aperture DIC H oil objective lens (Nikon). 
Images were taken using a Zeiss camera (AxioCam MR, Germany) and they were 
processed using Zen 2011 software (blue edition, Zeiss) and Quantified with Image J 
(V1.47, NIH). 
Clot Retraction 
Washed platelets from WT and KO mice were prepared and adjusted to 3 X 108/ml in 
HEPES Tyrode buffer (pH 7.4). During platelet preparation, cuvettes with 100 µl 10% 
sodium dodecyl sulfate polyacrylamide gel (SDS PAGE) at the bottom were prepared 
and soaked in HEPES Tyrode buffer (pH 7.4). Platelets were then supplemented with 
0.5 mg/ml human fibrinogen (Sigma) and 1 mM CaCl2. Immediately after mixing 
platelets with 0.1 U/ml thrombin in the presence or absence of the indicated 
treatment, platelets were transferred to the cuvettes and clot retraction was started. 
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Images were taken at the indicated time points. Clot volume was measured using 
Image J v1.47 and normalized to the initial volume. Analysis was done using SigmaPlot 
12.0.  
Endocytosis of Biotinylated-fibrinogen In vivo 
Biotin-fibrinogen was synthesized based on manufacture’s protocol using EZ-LinkTM 
sulfo-NHS-Biotinylation Kit (Thermo Scientific) and human fibrinogen (Sigma) in PBS. 
WT and KO mice were anaesthetized by isoflurane and then injected with 200 µl 5 
mg/ml labeled fibrinogen via retro-orbital plexus using 27 1/2 G needle. After 24 hours, 
mice were euthanized and platelets were harvest as described above. Platelet lysates 
were prepared and subjected to western blot with streptavidin-alkaline phosphatase 
conjugates.  
Preparation of GST-GBDs (Activated GTPase Binding Domains) 
pGEG-5X/GGA3 (Arf6 binding domain, VHS-GAT) was a generous gift from Dr. Julie G. 
Donaldson (NIH). pGEX-KG/mousePAK3 (Rac/Cdc42 binding domain, RBD) was kindly 
provided by Dr. Douglas A. Andres (University of Kentucky, Lexington, KY). These 
prokaryotic expression plasmids were transformed into the RosettaTM(DE) E coli and 
the positive clones were cultured in 25 ml LB/amp/cam media (100 µg/ml ampicillin 
and 35 µg/ml chloramphenicol) O/N at 37°C. The bacteria were harvested by 
centrifugation at 4,500x g for 15 min and the pellets were resuspended in 1L of fresh 
LB/amp/cam media. Protein expression was induced, when the OD600 of the culture 
reached 1, with 1 mM IPTG for 4 hours. The cells were harvested and processed 
immediately or kept frozen at -80⁰C. The cells were resuspended in TBS (Tris-buffer-
saline, 50 mM Tris/HCl, 147 mM NaCl) containing 1 mM dithiothreitol (DTT) and 1X 
protease inhibitors (20 µg/mL Leupeptin, 20 µg/mL Chymostatin, 20 µg/mL Pepstatin 
A, 10 µg/mL Antipain). The cells were then disrupted by passing the suspensions 
through a French Press three times at 12,000 psi. The lysates were cleared by 
centrifugation at 100,000 x g for 1 hour at 4°C. The supernatants were further clarified 
by passage through a 0.2 µm nylon filter. After mixing with glycerol (10% final, v/v), 
the supernatants were aliquot and stored at -80°C. The ratio of supernatant to 
glutathione beads (v to v) was determined by glutathione agarose beads binding assay. 
Different amount of clarified lysates were incubated with 10 μL beads for 1 hour at 
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4 °C. The beads complex was then washed three times with HEPES wash buffer and 
the bound proteins were eluted by 2X SDS sample buffer with 5 min boiling. The 
samples were analyzed by SDS-PAGE and subsequently stained by Coomassie blue. 
The sample with the saturation binding was selected to determine the optimal ratio 
for the following pull-down assay. 
Small GTPase Pulldown Assay 
Washed platelets (4 X 108/ml, 500 µl), which were kept resting or stimulated by 
agonists for indicated times in the aggregometer, were lysed with equal volumes of 
2X ice-cold lysis buffer (pH 7.4, 20 mM HEPES/KOH, 128 mM NaCl, 9 mM MgCl2, 2% 
Triton X-100, 0.2% SDS, 1% sodium deoxycholic acid, 20% Glycerol, and 2 mM 
benzamidine) containing 2X EDTA-free protease inhibitors cocktail. Platelet lysates 
were either processed immediately or stored at -80°C. For assay, the samples were 
thawed, transferred to Eppendorf tubes, and clarified by centrifugation at 15,000 x g 
for 5 min at 4°C. Sixty microliters of supernatant were used as input and 850 µl was 
incubated for 45 min at 4°C with a specific effector binding domain bound to 
glutathione-agarose. Specifically, all six Arf isoforms [477, 478] were recovered on 
GST-human GGA3VHS-GAT (1-133), Rac and Cdc42 [479] were recovered on GST-mouse 
PAK3RBD(397-518). The bound material was recovered by centrifugation at 500 x g for 12 
sec and washed 3 times with wash buffer (pH7.4, 20 mM HEPES, 128 mM NaCl, 2 mM 
MgCl2, 1% Triton X-100, 10% Glycerol). Input was prepared by adding 40 µl 5X sample 
buffer (62.6 mM Tris, pH6.8, 2% SDS, 5% Glycerol, 2% β-mercaptoethanol, 0.01% 
Bromophenol blue). Bead-bound material was dissolved in 80 µl 2X sample buffer. 
Samples were immediately used or kept at -20°C after boiling at 95°C for 5 min. 
Separation of Supernatant (Detergent-soluble) and Pellet (Detergent-insoluble) 
Washed human platelets (500 µl, 4 X 108/ml) was pretreated with indicated inhibitors 
and then were either kept resting or stimulated with agonists for 5 min in the 
aggregometer. The reactions were terminated with 2X ice-cold lysis buffer (HEPE/KOH, 
pH7.4, 2% Triton-X 100 or 2% NP-40, 127 mM NaCl, 5 mM MgCl2, 20% glycerol, 2 mM 
sodium orthovanadate, 2 mM benzamidine) containing 2X protease inhibitor cocktail. 
After incubation on ice for at least 30 min, the platelet lysates were clarified by 
centrifugation at 15,000x g for 10 min to remove detergent-insoluble material (e.g. 
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actin cytoskeleton and lipid rafts). The pellet were dissolved in 100 µl 1X sample buffer 
and 80 µl supernatant (detergent soluble fractions) was treated with 1X sample buffer. 
Immunoprecipitation/Co-immunoprecipitation 
Washed platelets (500 µl, 4 X 108/ml) were prepared as described above and kept at 
resting or stimulated with agonists for the indicated time at 37°C in the aggregometer. 
Platelets were pretreated with indicated inhibitors prior to stimulation. The reactions 
were terminated by adding equal volume of 2X ice-cold immunoprecipitation buffer 
(20 mM HEPE/KOH, pH 7.4, 128 mM NaCl, 9 mM MgCl2, 2% Triton-X 100, 20% glycerol, 
2 mM sodium orthovanadate, 2 mM benzamidine, 2 mM EGTA) containing 2X 
protease inhibitor cocktail and phosphatases inhibitor cocktail. Platelets lysates were 
incubated on ice for at least 30 min and then clarified by centrifugation at 15,000 X g 
for 10 min at 4°C. The supernatant (80 µl) was used as input and 850 µl of the 
remaining supernatant were first incubated with 10 µl protein-A agarose for 30 min at 
4°C to remove non-specific binding proteins. The resulting supernatants were then 
incubated with the indicated antibodies bound to protein-A agarose for 2 hours at 4°C. 
The bound proteins were recovered by centrifugation and washed 3 times with 1X ice-
cold IP lysis buffer. The bound proteins were eluted by addition of 1X sample buffer. 
Input was also prepared in 1X sample buffer. All samples were then boiled for 5 min 
and subjected to western blotting. 
Western Blotting and Quantification 
Protein samples were boiled at 95°C for 5 min and then loaded into sodium dodecyl 
sulfate-polyacrylamide gel (SDS-PAGE). After separation, the proteins were 
transferred electrophorectically to Immobilon-P polyvinylidene fluoride membrane 
(PVDF, Milipore, Bedford, MA) using a constant voltage (100 V) for 1 hour. PVDF 
membranes were blocked with blocking buffer [5% non-fat dried milk in TBST (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Tween-20)] for 1 hour at RT. Membranes were 
then incubated with appropriately diluted primary antibody in blocking buffer 
overnight (O/N) at 4°C. After wash for 3X 5 min with TBST, membrane was incubated 
with 1 to 10,000 diluted -secondary antibodies in blocking buffer for 45 min at RT. 
After another 3X 5 min washes with TBST, membranes were incubated with substrate 
and processed for imaging.  
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For HRP-conjugated secondary antibody, enhanced chemiluminescence (ECL) 
substrate was used. After incubation with substrate, membrane was scanned in 
ChemiDocTM MP system (BioRad, Life Science Research, Hercules, CA) and signal was 
quantified using Image Lab Software.  
For alkaline phosphatases-conjugated secondary antibody, enhanced 
chemofluorescence (ECF) substrate (GE healthcare, Piscataway, NJ) was used. 
Membrane was placed on a transparent film (3M, St. Paul, MN) and incubated with 
substrate. The fluorescent signal was detected using TyphoonTM 9400 (Amersham 
Biosciences) or Fluorescent imager (GE Healthcare). Quantification was performed 
using ImageQuantTL 5.2 software (Amersham Biosciences).  
Measurement of F-actin in Platelets 
F-actin content in platelets has been measured by a spectrofluorometer-based assay 
system. Resting and stimulated platelets (2 x 107) were fixed and permeabilized by an 
equal volume of F-actin staining buffer (10 mM PIPES, pH 6.9, 20 mM KH2PO4, 5 mM 
EGTA, 2 mM MgCl2, 0.2% Triton X-100, 3% glutaraldehyde, 2 μM TRITC-phalloidin) with 
constant rotation for 1 hour at RT. F-actin fraction was collected by centrifuge at 
15,000 x g for 5 min and washed once with F-actin wash buffer (10 mM PIPES, pH 6.9, 
20 mM KH2PO4, 5 mM EGTA, 2 mM MgCl2, 0.1% Saponin). Bound TRITC-phalloidin was 
extracted by incubating the pellet with 300 μl methanol at RT for 1 hour. Freed 
phalloidin was separated by centrifuge at 15,000 x g for 5 min. The fluorescence 
intensities of samples were measured using a microplate spectrofluorometer 
SpectramMax GeminiXS (Molecular Devices, Sunnyvale, CA) and analyzed with 
SoftMax Pro software (Molecular Devices). 
Ex vivo FITC-fibrinogen Uptake Assay 
Washed WT and KO platelets were resuspended at concentrations of 5 X 108/ml in 
HPEPS Tyrode Buffer containing 1% BSA and 1 mM CaCl2. Platelets (100 µl) were 
incubated with 0.05 mg/ml FITC-fibrinogen for 1 hour at 37°C. Platelets were 
subjected to centrifugation at low speed to avoid activation and resuspended in an 
equal volume of platelet poor plasma (PPP) or HEPES Tyrode Buffer containing BSA 
and CaCl2. Platelets were then incubated for 3 hours at 37°C and fixed with 2 % 
paraformaldehyde at 4°C overnight. Platelets were recovered by centrifugation and 
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resuspended in 15 µl HEPES Tyrode buffer. Microscopic slides with 5 µl platelets mixed 
with 1 µl Trypan blue (stock 4%) were prepared and visualized using Nikon Eclipse 
E600 microscope (Nikon, Melville, NY) with a 100X/1.40 numeric aperture DIC H oil 
objective lens (Nikon). Images were taken using Zeiss camera (AxioCam MR, Germany). 
Images were processed using Zen 2011 (blue edition, Zeiss). As a metric of FITC-uptake, 
the number of FITC-positive granules per platelet was counted. 
Tail Bleeding Assay 
Mice from WT and KO groups (4-6 weeks of age) were anaesthetized by 
intraperitoneal injection with (Fort Dodge SOURCE, 75 mg/kg). The tail was transected 
3 mm from the tip and immediately immersed in 37°C saline. The time from 
transection to bleeding cessation was recorded. Mice were watched for an additional 
minute to monitor re-bleeding events. The recordings were terminated at 10 min if 
prolonged bleeding occurred and the bleeding was stopped manually. The data was 
analyzed using the Logrank test. 
FeCl3-induced Carotid Artery Injury Model 
Mice from age-matched WT and KO groups were anaesthetized by intraperitoneal 
injection with Avertin (0.2 g/kg). Mice were placed on a heating pad with tape on the 
legs and thread on the teeth to maintain their position. The left carotid artery was 
surgically exposed and the ultrasound probe (Transonic probe 0.5P) was place 
underneath. The artery was immersed with saline during the entire recording period. 
Flow in the artery was recorded using the TS420 Transonic System. A stable baseline 
signal was recorded for 3 min prior to placing a FeCl3-soaked filter paper (for 3 min) 
on the site supported by a plastic wedge. After removal of the filter paper, flow was 
measured until it ceased and the time was recorded. Mouse was monitored for an 
additional minute to look for unstable thrombus formation. The recordings were 
terminated by 30 min. Mice were euthanatized at the end of experiments. The data 
was analyzed using the Logrank test.  
Study Approval 
All animal work was approved by the Institutional Animal Care and Use Committee at 
the University of Kentucky. Since banked platelet units were anonymized, there is no 




The data from bleeding time and occlusion assays were analyzed using the Logrank 
test. The data from secretion assays and FACS-based experiments were analyzed by 
two-way ANOVA. A one-tailed Student’s t-test was used to analyze the properties of 




Chapter Three: Role of Arf6 in Murine Platelets 
Introduction 
Endocytic trafficking of platelet surface receptors plays a role in the accumulation of 
granule cargo (i.e. fibrinogen and VEGF) and thus could contribute to hemostasis, 
angiogenesis, or inflammation. However, the mechanisms of platelet endocytosis are 
poorly understood. The small GTP-binding protein, ADP-ribosylation factor 6 (Arf6), 
regulates integrin trafficking in nucleated cells; therefore, we posited that Arf6 
functions similarly in platelets. To address this, we generated platelet-specific, Arf6 
knockout mice. Consistent with our hypothesis that Arf6 controls integrin αIIbβ3-
trafficking and thus uptake of fibrinogen Arf6-/- platelets had a fibrinogen storage 
defect, though other cargo were unaffected. Additionally, platelets from Arf6-/- mice 
injected with biotinylated-fibrinogen, showed lower accumulation of the modified 
protein than did WT mice. Resting and activated αIIbβ3 levels, measured by FACS, 
were unchanged in Arf6-/- platelets. Arf6-/- platelets had normal agonist-induced 
aggregation and ATP release; however, they showed faster clot retraction and 
enhanced spreading, which appears due to altered αIIbβ3 trafficking since myosin light 
chain phosphorylation and Rac1 activation, in response to thrombin, were unaffected. 
Arf6-/- mice showed no hemostasis defect in tail-bleeding or FeCl3–induced carotid 
injury assays. This is the first report, using animal models, to identify a role for Arf6 in 
integrin αIIbβ3 trafficking in platelets. 
Generation of Platelet-specific, Arf6 KO Mice 
Mouse embryos with a floxed Arf6 gene were kindly provided by Dr. Yasunori Kanaho 
at University of Tsukuba in Japan [474] and recovered by the Jackson Laboratory (Bar 
Harbor, ME). Platelet-specific Arf6 KO mice were generated by crossing Arf6-gene 
floxed mice with PF4-Cre mice that were regularly used by our laboratory to generate 
mouse strains with specific, protein-deficiencies in platelets [35]. The strategy of 
generating the mice is shown in Figure 1A. For experiments, mice from an Arf6-
floxed/Cre- (referred as WT hereafter) and Arf6-floxed/Cre+ (referred as KO hereafter) 
cross were used. The genotypes of all mice were determined by PCR. Isolated genomic 









Figure 1 Generation of Platelet-specific, Arf6 KO Mice. (A) Strategy of generating 
platelet-specific, Arf6 KO mice. Arf6 gene-floxed mice were first crossed with PF4-Cre 
mice. For experiments, mice were generated by intercross of Arf6flox/flox/PF4-Cre+ and 
Arf6flox/flox/PF4-Cre-. (B) DNA electrophoresis of PCR products of Arf6 gene and Cre 
gene. PCR production was amplified using the primer and condition described in 
method section. A WT control, the one on the right, was used as control. Data is 
representative of at least three independent experiments. (C) Protein profile of Arf6 
WT and KO platelets. Washed platelets (1 X 107) from WT and KO were loaded. 
Indicated proteins were probed by western blotting using corresponding antibodies. 
Actin was used as a loading control. Data is representative of at least three 
independent experiments. (D) Levels of plasma fibrinogen in Arf6 WT and KO mice. 
Equal amount of plasma from WT and KO mice were used to measure fibrinogen levels 
in plasma by western blotting using anti-fibrinogen antibody. Each lane represents 




amplification using primers mentioned in Chapter 2. Figure 1B is a representative 
image of the electrophoretic patterns of the PCR products. Each lane represents a 
single mouse. As expected, the PCR product of the floxed Arf6 gene is bigger than the 
WT allele due to the insertion of flox sites. The PCR product for the PF4-Cre transgene 
is also shown. Various proteins in WT and KO platelets were measured by western 
blotting. As shown in Figure 1C, Arf6 protein levels were reduced by ~95% in platelets 
from Arf6 KO mice. The expression levels of other proteins were not affected: Arf1/3, 
Rho family members (Rac1, Cdc42, and RhoA), integrin β3 subunit, and granule 
membrane markers (P-Selectin and VMAT2, representing α-granule and dense-
granule, respectively).  
Arf6 KO Platelets were Defective in Uptake of Fibrinogen  
Platelets contain a diverse set of proteins in their granules. At least some are not 
synthesized by platelets or by their precursor cells, megakaryocytes. In fact, these 
proteins are derived from plasma, and are internalized and stored in platelet granules 
(mostly alpha granules). These proteins include fibrinogen, immunoglobulin (lgG), 
laminin, etc. Uptake of these proteins by platelets is mediated by either receptor-
mediated endocytosis, e.g. fibrinogen, or fluid phase endocytosis, e.g. lgG. Therefore, 
the levels of these proteins in platelets are indicative of the cargo endocytosis. Arf6 is 
an important element of the endocytic machinery in several different cell types [294, 
316, 317, 319]. To determine if Arf6 plays a role in platelet endocytosis, we measured 
the levels of several granule cargo, e.g. fibrinogen, fibronectin, vitronectin, von 
Willebrand Factor (vWF), platelet factor 4 (PF4), Sema3F, and lgG. Among them, 
fibrinogen is known to be internalized through an αIIbβ3 integrin-mediated process. 
As a control for the analysis, fibrinogen levels were severely decreased in platelets 
from β3 knockout mice (Figure 2A). Interestingly (and consistent with our hypothesis), 
fibrinogen levels in Arf6 KO platelets were ~50% lower compared to WT (Figure 2B). 
To exclude the possibility that the decreased fibrinogen levels were due to lower levels 
of fibrinogen in plasma, plasma fibrinogen was measured and was shown to be 
comparable between WT and KO (Figure 1D). These data suggest that Arf6 KO 







Figure 2 Arf6 KO platelets had storage defect on fibrinogen, but not other cargo. (A) 
Comparison of fibrinogen levels between WT and β3-/- KO platelets. Platelets (1 X 107) 
were loaded each lane and indicated proteins were probed using corresponding 
antibodies. GIT1 was used as a loading control. Blots shown are representative of at 
least two independent experiments. (B) Endogenous fibrinogen levels in WT and KO 
platelets were determined by western blotting. Platelets (1 X 107) were loaded each 
lane and indicated proteins were probed using corresponding antibodies. Each lane 
represents platelets from a single mouse. RabGDI was used as a loading control. 
Quantification of fibrinogen levels was performed using ImageQuantTL and analyzed 
by SigmaPlot 12.0. (C) Comparison of biotinylated fibrinogen levels between WT and 
KO platelets. Platelets were harvested 24 hours post retro-orbital injection of 
biotinylated fibrinogen. Each lane represents platelets from a single mouse. Platelets 
(1 X 107) were loaded in each lane and indicated proteins were probed using 
corresponding antibodies. Actin was used as a loading control. A mouse with no 
injection was included as a control. Quantification of biotinylated fibrinogen levels was 
performed using ImageQuantTL and analyzed by SigmaPlot 12.0. (D) Comparison of 
different cargo in WT and KO platelets. Indicated cargo were measured by western 
blotting using the corresponding antibodies. Actin was used as a loading control. 
Quantification was performed using ImageQuantTL and ratio of KO to WT was 
calculated. The dash line represents ratio of 1 (KO/WT). Blots shown are 




uptake. To further test this hypothesis, WT and KO mice were injected with 
biotinylated fibrinogen and platelets were harvested after 24 hours. As shown in 
Figure 2C, biotin- conjugated fibrinogen levels in KO platelets were ~50% less relative 
to WT. It should be noted that under these assay conditions, the level of biotinylated 
fibrinogen in plasma is similar between WT and KO as the same amount of biotinylated 
fibrinogen was injected. 
It has been reported that both megakaryocytes and platelets can take up biotin-
fibrinogen from plasma in an αIIbβ3-dependent manner [29]. At this point, we were 
not able to define which cell was defective in endocytosis of biotin-fibrinogen, 
although it was very likely that both could be defective. Regardless, these data 
indicated that Arf6 plays a role in αIIbβ3 integrin-mediated fibrinogen uptake in 
platelets and/or megakaryocyte. To determine if Arf6 had a global role on cargo 
storage and uptake, the levels of other proteins were determined. Surprisingly, none 
of the other proteins tested were significantly affected by Arf6 knockdown as shown 
in Figure 2D, including fibronectin (ligand of α5 integrin), vitronectin (ligand of αv 
integrin), Sema3F (ligand of neuropilin), and lgG (target of fluid phase endocytosis). 
These data suggest that Arf6 specifically regulates fibrinogen uptake by platelets or 
megakaryocytes.  
To further test whether Arf6 KO platelets are defective in fibrinogen uptake ex vivo, 
platelets were incubated with FITC-fibrinogen and examined by epi-fluorescence 
microscopy (Figure 3A). Clearly, Arf6 KO platelets have lower signal intensity 
compared to WT. Quantification data in Figure 3B shown that Arf6 KO platelets have 
more cells that contain fewer FITC-labelled punctae per platelet, consistent with a 
lower uptake of FITC-fibrinogen. Taken together these in vivo and ex vivo results 
demonstrate that Arf6 KO platelets are specifically defective in uptake of fibrinogen, 
but not the other cargo examined.  
Arf6 KO Platelets Had Normal Morphology  
Since fibrinogen is an abundant cargo protein in platelet α-granules, we next examined 
whether Arf6 deficiency causes any morphology defect. Using EM, platelet 









Figure 3 Uptake of FITC-fibrinogen ex vivo was impaired in Arf6 KO platelets. (A) 5 X 
108/ml washed platelets were incubated with FITC-fibrinogen (0.05 mg/ml) for 1 hour 
at 37°C. After washing away the extracellular FITC-fibrinogen, platelets were 
continued to incubate with plasma for another 2 hour. Platelets were fixed with 2% 
paraformaldehyde over night at 4°C and subjected to fluorescence microscope. The 
surface signal was quenched by Trypan blue (0.1%) and representative images of area 
of interested were presented. Images shown are representative of three independent 
experiments. (B) Quantification of A. The number of FITC-positive puncta was 
manually determined and platelets were grouped based on that number. The 
percentage of each group to total was calculated and plot in bar graph. Statistics 









Figure 4 Arf6 KO platelets had normal morphology. Washed platelets from WT and 
KO mouse were prepared in HEPES tyrode buffer (pH 7.4) and adjusted to 4 X 108/ml. 
Resting or thrombin-stimulated platelets were preceded for electron microscope 
analysis (see Chapter 2). Images were taken using a Hitachi H-7000 transmission 






Table 2 Characteristics of Blood Cells from WT and KO 
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Though there was no overt change in the morphology of the platelet granules, the 
Arf6 KO platelets were slightly smaller which was consistent with whole blood 
counting data (Table 2). This observation was perhaps expected given that platelets 
from fibrinogen-deficient mice have normally appearing α-granules [480]. These data 
demonstrated that Arf6-deficiency does not cause any dramatic change in overall 
platelet and platelet granule morphology. 
Arf6 KO Platelets Had Normal Surface Expression Levels of Integrin αIIbβ3 
Several reports including the data presented here (Figure 2A) show that fibrinogen 
uptake by platelets is mediated by integrin αIIbβ3 [29]. Therefore, reduced fibrinogen 
levels in Arf6 KO platelets suggest that Arf6 may be involved in endocytosis of and/or 
subsequent trafficking of integrin αIIbβ3 in platelets. In nucleated cells Arf6 plays an 
active role in both endocytosis and subsequent trafficking and recycling pathways of 
integrins [216, 317, 319]. 
Defects in any of these pathways could lead to a fibrinogen-storage defect. If Arf6 
participates in the initial steps of the endocytosis process, higher surface levels of 
αIIbβ3 integrin might be expected because the integrin is not internalized. Conversely, 
if Arf6 is involved in a recycling process, lower surface levels of αIIbβ3 integrin might 
be expected because the integrin is not returned to the surface. Alternatively, if αIIbβ3 
integrin trafficking routes are altered by loss of Arf6, there may be no significant 
difference in surface integrin levels. To distinguish these possibilities, the surface 
levels of αIIbβ3 integrin were measured by flow cytometry. Washed WT and KO mouse 
platelets, either kept resting or stimulated with thrombin, were labeled for total and 
activated αIIbβ3 integrin using anti-CD41/61 antibody (Figure 5A) and Jon/A antibody 
(Figure 5B), respectively. Surprisingly, WT and KO platelets do not show any significant 
difference in either total or activated αIIbβ3 integrins. This data is consistent with an 
alteration in the αIIbβ3 integrin trafficking route and not a defect in internalization 
from or recycling to the plasma membrane. However, it is also possible that the FACS 
assay is not sufficiently sensitive to distinguish the small difference that is actually 








Figure 5 Arf6 KO platelets did not show any defect on the surface levels of total 
integrin αIIbβ3 and active integrin αIIbβ3 in both resting and thrombin-stimulated 
states. (A) Comparison of total surface levels of integrin αIIbβ3 using FITC-CD41/CD61 
antibody between WT (green) and KO (red) platelets in resting and stimulated states. 
No labeled platelets (black) were used as background control. (B) Comparison of 
surface level of active integrin αIIbβ3 using PE-Jon/A antibody between WT (green) 
and KO (red) platelets in resting and stimulated states. No labeled platelets (black) 
were used as background control. i to iii represents resting state, thrombin-stimulated 
state, and quantification of Geo mean of fluorescent intensity (GMFI), respectively. 




Integrin αIIbβ3 is the major receptor mediating platelet aggregation ex vivo. The 
surface level of activated αIIbβ3 is correlated with the degree of platelet aggregation. 
Consistent with the flow cytometry data, KO platelets, in response to various agonists, 
did not show significant defects in aggregation when compared to WT (Figure 6). 
Interestingly, Arf6 KO platelets had no defect in ATP release as monitored by lumi-
aggregometer. This is distinct from the observations reported previously [353] where 
Arf6 is suggested be essential for dense-granule secretion, as measured by ATP release. 
Arf6 Depletion Enhanced Platelet Spreading on Fibrinogen-Coated Surfaces and Clot 
Retraction 
Although there were no significant defects in the surface levels of integrin αIIbβ3, we 
wondered whether the dynamics of integrin trafficking were affected in Arf6 KO 
platelets since platelet uptake of fibrinogen from plasma is a dynamic process both in 
vivo and ex vivo. As possible metrics of such a process, we first looked at the static 
adhesion of platelets on fibrinogen-coated surfaces. As shown in Figure 7A, there is 
no significant difference in the number of adhered platelets between WT and KO after 
30 min incubation on fibrinogen-coated surfaces.  
As an additional metric of integrin trafficking, the rate of platelet spreading on 
fibrinogen-coated surfaces was probed by measuring platelet surface area versus time. 
Inhibition of integrin β1 trafficking by Arf6 depletion in HeLa cells results in diminished 
cell spreading on fibronectin, integrin β1’s substrate [317]. However, manipulation of 
Arf6-GTP levels by over-expression of a GAP, increased axonal growth, which is a sense 
of polarized spreading [220]. Arf6 KO platelets had larger surface areas as early as 60 
min into the incubation period, compared to WT (Figure 7B). At 90 and 120 min, Arf6 
KO platelets were significantly larger than WT (Figure 7B-D). These data indicate that 
Arf6 KO platelets spread significantly faster on fibrinogen-coated surfaces than WT 
controls. A possible explanation for these results is that integrin αIIbβ3 is more 
effectively expressed on the platelet surface thereby increasing the efficacy of the 
platelet contacts with fibrinogen. If depletion of Arf6 leads to this effect, as our results 
suggest, it implies that Arf6 controls integrin αIIbβ3 turnover/trafficking at the cell 








Figure 6 Arf6 KO platelets had no aggregation defect. Washed platelets from WT 
(black) and KO (grey) mice were freshly prepared and adjusted to 2.5 X 108/ml in 
HEPES Tyrode’s buffer. Thrombin (A), Collagen (B), U46619 (C), and ADP (D) were used 
to stimulate platelet aggregation in stirring condition at 37°C in aggregometer. The 
concentrations of agonists were indicated. ATP release was monitored using CHRONO-
LUME reagent (Chrono-log) while platelet aggregation was performed. Data shown 









Figure 7 Arf6 KO platelets had enhanced spreading but normal static adhesion. (A) 
Quantification of static platelet adhesion on fibrinogen- and BSA-coated surface. 
Washed calcein-labelled platelets (2.5 X 108/ml) from WT and KO mouse were 
incubated on fibrinogen- or BSA-coated surface for 30 min at 37°C. Using plate reader 
with excitation/emission at 485/538 nm, the number of adhered platelets was 
measured referral to the standard curve with fixed number of platelets from each 
strain. Each bar represents platelets from a single mouse. Quantification analysis was 
performed using SigmaPlot 12.0. (B) Quantification of surface area of platelets spread 
on fibrinogen-coated surface at indicated time points. Washed platelets from WT and 
KO mouse were adjusted to 2.0 X 107/ml and supplemented with 1 mM Ca2+. Platelets 
were then incubated on fibrinogen-coated surface for indicated amount of time and 
fixed with 4% paraformaldehyde. DIC images were taken using Nikon Eclipse E600 
microscope (Nikon, Melville, NY) with a 100X/1.40 numeric aperture DIC H oil 
objective lense (Nikon). Images were taken using Zeiss camera (AxioCam MR, 
Germany). Image was processed by Zen 2011 (blue edition, Zeiss) and Quantified by 
image J (V1.47, NIH). (C-D) Representative DIC images of WT (C) and KO (D) platelet 
spreading at 120 min point. Spreading data are representative of at least three 




integrin α9β1, which is important for controlling integrin-dependent axon growth. 
Overexpression of ACAP1, a GAP protein for Arf6, inactivated Arf6, which in turn 
increased the recycling of integrin α9β1 and increased axon growth [220]. Our data 
could be considered consistent with such a phenotype. Loss of Arf6 (like inactivation 
of Arf6 in neurons) might increase integrin αIIbβ3 recycling (or divert it to an alternate 
route) and thereby enhance platelet spreading. Following this line of reasoning, we 
performed another assay that is a potential metric of integrin αIIbβ3 function, platelet 
clot retraction. Consistent with the spreading data above, Arf6 KO platelets had faster 
clot retraction times (Figure 8). Fibrinogen is added exogenously to these assays and 
is in excess. The increased clot retraction supports the contention that loss of Arf6 
increases the efficacy of integrin αIIbβ3 engagement with substrate. Since 
downstream signaling by integrin αIIbβ3 plays an important role in clot retraction 
[481], myosin light chain phosphorylation (Figure 9B), tyrosine phosphorylation 
profiles (Figure 9A), and Rac1 activation (Figure 10) were examined. Surprisingly, we 
could not detect any overt differences between WT and KO. Consistently, F-actin 
formation was also not affected in Arf6 KO platelets following thrombin stimulation 
(Figure 11). These data exclude the possibility that the enhanced phenotypes (clot 
retraction and spreading) were due to up-regulation of some signaling step that is 
downstream of integrin αIIbβ3. However, as noted with the FACS analysis, these 
assays may not be sufficiently sensitive to determine a small difference that actually 
exists between WT and KO platelets. Together, the clot retraction and spreading data 
demonstrate that loss of Arf6 affects normal platelet-matrix contacts and alters their 
efficacy. The FACS data, despite its caveats, is not consistent with a wholesale change 
in integrin αIIbβ3 surface expression and the signaling analysis confirms that there is 
no overt change in the steps thought to be downstream of integrin αIIbβ3 engagement. 
Based on Arf6’s role in other cell types, i.e. neurons, these data are best explained by 
Arf6 playing a role in the dynamics or routing of integrin αIIbβ3 trafficking in the 
platelets. 
Inhibiting Dynamin-dependent Endocytosis Enhanced Platelet Clot Retraction 
As an attempt to confirm our conclusions about Arf6’s role, we sought to disrupt 








Figure 8 Arf6 KO platelets had enhanced platelet clot retraction. (A) Washed platelets 
from WT and KO mice were adjusted to 3 X 108/ml and supplemented with 0.5 mg/ml 
human fibrinogen and 1 mM Ca2+. Clot retraction was initiated in cuvette with 0.1 
U/ml thrombin. Images were taken at the indicated time points. (B) Quantification of 
clot retraction. Clot size in (A) were measured using image J v1.48 and percentage of 
clot size to time 0 were determined and then analyzed using SigmaPlot 12.0. Clot 









Figure 9 Arf6 KO platelets did not show any defect on global tyrosine 
phosphorylation and myosin light chain phosphorylation upon thrombin stimulation. 
(A) Washed platelets from WT and KO mice were prepared at 4 X 108/ml in HEPES 
Tyrode’s buffer (pH 7.4) and kept resting or stimulated with 0.1 U/ml thrombin for 5 
min. The reaction was stopped by addition of SDS-PAGE sample buffer containing both 
protease inhibitor cocktail and phosphatase inhibitor cocktail. The lysates were 
subjected to western blotting for the global tyrosine-phosphorylation profile. Actin 
was used as a loading control. Data are representative of at least two independent 
experiments. (B) Washed platelets from WT and KO mice were prepared at 4 X 108/ml 
in HEPES Tyrode’s buffer (pH 7.4) and kept resting or stimulated with 0.1 U/ml 
thrombin for the indicated times. The reaction was stopped by addition of SDS-PAGE 
sample buffer containing both protease inhibitor cocktail and phosphatase inhibitor 
cocktail. The lysates were subjected to western blotting for MLC-P profile. Actin was 









Figure 10 Arf6 KO platelets did not show defect on Rac1 activation. (A) Rac1 
activation upon thrombin stimulation. Washed platelets from WT and KO mice were 
prepared at 4 X 108/ml in HEPES Tyrode’s buffer (pH 7.4) and kept resting or stimulated 
with 0.1 U/ml thrombin for the indicated times. The reaction was stopped by addition 
of 2 X GTPases-pulldown lysis buffer containing both protease inhibitor cocktail. Rac1-
GTP was pulled down based on the methods described in method section. The pellets 
(Rac1-GTP) and the supernatant (total Rac1) was subjected to western blotting. (B) 
Quantification of A. Quantification of Rac1-GTP and total Rac1 level was performed 
using ImageQuantTL and the ratio of Rac1-GTP/Total Rac1 was calculated and plotted 









Figure 11 Arf6 KO platelets and GIT1 KO platelets had normal F-actin content in 
resting and thrombin stimulated platelets. Platelets (2 X 107) were either kept resting 
or stimulated with 0.1 U/ml thrombin for 5 min. F-actin level in platelets were 
measured according to the method section. F-actin levels in thrombin-stimulated 
platelets were normalized to its corresponding resting states. Data is representative 




analysis has suggested that endocytosis of integrins in platelets is clathrin- and 
dynamin-mediated process [233]. Therefore, disrupting integrin αIIbβ3 endocytosis by 
inhibiting dynamin activity could recapitulate the phenotype of the Arf6 KO platelets. 
To test this hypothesis, a dynamin inhibitor, dynasore, was used. As shown in Figure 
12, the presence of dynasore promotes platelets clot retraction, which suggests that 
dynamin-mediated endocytosis plays a role in clot retraction. It is likely that this 
enhanced clot retraction is due to inhibited endocytic trafficking of integrin αIIbβ3 by 
dynasore. However, we could not exclude other possibilities at this point, for example, 
endocytic trafficking of other receptors, like P2Y receptors, could also be inhibited by 
dynasore treatment [52].  
Arf6 KO Mice Had no Defect in Arterial Thrombosis and Hemostasis 
Given the effects on spreading and clot retractions we next wanted to determine 
whether loss of Arf6 in platelets caused any overt effects on hemostasis and 
thrombosis. Hemostasis was monitored using a tail-bleeding-time assay and 
thrombosis was monitored using a FeCl3-induced carotid artery injury model. It should 
be noted that in both assay systems, defective hemostasis and/thrombosis is readily 
detectible, but enhancements are more difficult to document. Compared to WT, we 
did not detect any defect in tail-bleeding or in FeCl3-induced, occlusive thrombosis in 
the Arf6 KO mice (Figure 13). These data suggest that although Arf6 depletion caused 
enhanced spreading and clot retraction probably via regulating integrin αIIbβ3 
trafficking in platelets, this effect may not sufficient to grossly influence thrombus 
formation and hemostasis in vivo. 
Conclusions 
In this chapter Arf6’roles in platelets has been further defined using platelet-specific, 
Arf6 knockout mice. Although depletion of Arf6 in mouse platelets did not affect 
platelet morphology, aggregation, and ATP release, Arf6 knockout did affect the 
loading of fibrinogen, but not other cargo examined. This phenotype suggests that 
integrin αIIbβ3-mediated uptake of fibrinogen by platelets is affected and indicating a 
role for Arf6 in the process. Enhanced spreading and clot retraction of Arf6 KO 
platelets suggests that Arf6 may play a role in the endocytic trafficking of integrin 
αIIbβ3, which is supported by the effects of the endocytosis inhibitor, dynasore, on 
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clot retraction. Given the ‘hyperactive’ phenotype of Arf6 KO platelets, Arf6 KO mouse 
might have hyper thrombotic phenotype, however that was not detectible in the assay 
systems that we used. More sensitive systems will be needed to fully appreciate the 












Figure 12 Dynasore enhanced mice platelets clot retraction. Washed mouse platelets 
were prepared in HEPES Tyrode’s buffer (pH 7.4) at 4.0 X 108/ml. Platelets were 
supplemented with 1 mM Ca2+ and 0.5 mg/ml fibrinogen. Clot retraction was initiated 
by 0.1 U/ml thrombin in the presence or absence of 80 µM dynasore. The images were 










Figure 13 Arf6 KO mice did not have any significant defect in thrombosis formation 
and hemostasis. (A) Tail bleeding assay. Mice from WT and KO group at 4-6 weeks age 
were anaesthetized by intraperitoneal injection with Ketamine (75 mg/kg). The tail tip 
was transected by 3 mm and immediately immersed in 37°C saline. The time from 
transection to bleeding cessation was recorded. Mouse was monitored for an 
additional minute to look for re-bleeding event. The recording was terminated by 10 
min. For the prolonged bleeding mice, bleeding was stopped manually. The data was 
analyzed using Logrank test. (B) FeCl3-induced Carotid Artery Injury model. Mice from 
WT and KO group at 8-12 weeks old were used. Fresh 4% FeCl3 applied on left carotid 
artery for 3 min was used to induce an injury. The time from removal of FeCl3 to blood 
flow cessation was recorded. Mouse was monitored for an additional minute to look 
for unstable thrombus formation. The recording was terminated by 30 min. Mice were 
















Chapter Four: Potential Role for GIT1 in Human Platelets 
Introduction 
Our previous work [414, 417] and the studies described in the previous chapter 
demonstrate that Arf6 is an important contributor to platelet function, particularly in 
integrin αIIbβ3-mediated functions. We and other groups [353] have shown that 
resting platelets maintain relatively high level of Arf6-GTP and that upon platelet 
activation, Arf6-GTP level decreased dramatically. Interestingly, blocking integrin 
αIIbβ3 outside-in signaling partially recovers Arf6-GTP levels, a phenotype that was 
also observed when β3 KO platelets were used. This suggests that there are two waves 
of signaling regulating Arf6 in platelets. A first wave that is initiated by agonist 
stimulation and a second wave that appears to require integrin αIIbβ3.  
As other Ras-like, small GTPase, Arf6 nucleotide states are regulated by two groups of 
proteins, GEFs and GAPs. However, it is still unknown which of the regulators present 
in platelets are responsible for controlling Arf6. Recent, comprehensive proteomics 
analysis [352] has identified several potential Arf6-specific GEFs and GAPs in platelets, 
including the GIT1 protein. For αIIbβ3 integrin-regulated loss of Arf6-GTP, the simplest 
explanation is the presence of an Arf6 GAP, whose activity is activated following 
integrin, outside-in signaling. Compared to other potential Arf6 regulators identified 
so far, the GIT1 protein has some unique features that make it a candidate for this 
scenario.  
GIT1 is a multi-domain protein, containing an N-terminal ArfGAP domain that is 
specific for Arf6 [422-424]. GIT1 has a C-terminal, paxillin-binding site (PBS), which 
allows it to bind paxillin, a focal adhesion protein, and thus to associate with integrins. 
GIT1 can be phosphorylated by kinases in focal adhesions, e.g. FAK and Src [437, 443, 
449, 450]. Thus, it was not surprising when GIT1 was found to be tyrosine-
phosphorylated downstream of αIIbβ3 integrin outside-in signaling in platelets [425]. 
Based on this observation, we hypothesized that GIT1 is a key Arf6GAP downstream 
αIIbβ3 integrin outside-in signaling, and thus is important for function.  
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A GIT1-containing Complex Translocated to a Detergent-insoluble Fraction upon 
Platelet Activation 
GIT1 could form complexes through interactions with several other proteins, including 
β-PIX. It has been shown that GIT1-containing complexes cycle between three 
subcellular localizations, cytoplasm, peripheral area and FAs. The first thing we sought 
to determine in platelets was whether GIT1-containing complexes changed locale 
upon platelet activation and become associated with a cellular compartment that is 
associated with αIIbβ3. For this, we performed a time-course experiment in which 
washed human platelets were stimulated with thrombin and the reactions stopped by 
addition of Triton X-100-containg lysis buffer at the indicated times. Detergent-
insoluble fractions (pellet) and detergent-soluble fractions (supernatant) were 
separated by centrifugation and analyzed by western blotting. RabGDI is a cytosolic 
protein that was used as a marker for fractionation efficacy. As shown in Figure 14, 
there was no detectable RabGDI in the Triton X-100 insoluble, pellet fraction. It should 
be noted that most proteins tested, except integrin and actin, are soluble in resting 
platelets. Upon platelet activation by around 60 seconds, GIT1, β-PIX, FAK, Rac1, Arf6 
and the integrin β3 subunit all redistributed into the pellet fraction which may be a 
αIIbβ3 integrin-containing actin cytoskeleton structure.  
Translocation of GIT1-containing Complexes to the Detergent-insoluble Fraction 
Depended on αIIbβ3 Integrin Outside-in Signaling and Arf6 Activity 
Next, we wondered if blocking integrin αIIbβ3 outside-in signaling would affect 
translocation of the GIT1-containing complex. As shown in Figure 15, pretreatment of 
washed platelets with RGDS peptide, an inhibitor of integrin αIIbβ3 binding to 
substrate i.e. fibrinogen, completely blocked translocation of GIT1-related proteins to 
the Triton X-100 insoluble fraction, suggesting that integrin αIIbβ3 outside-in signaling 
is important for this complex translocation and supporting our hypothesis that GIT1 is 
a signaling component downstream αIIbβ3 outside-in signaling. Myristoylated-Arf6 N-
terminal peptide (mryArf6p), an inhibitor, which blocks interactions between Arfs and 
GAPS and that was previously used to block the loss of Arf6-GTP in platelets [414], was 







Figure 14 Translocation of GIT1-containing complex upon platelet stimulation is 
time-dependent. Washed platelets (6 × 108 platelets/mL) were pre-incubated for 2 
min in an aggregometer then stimulated with 0.1 U/mL thrombin for the indicated 
times. Platelets were lysed in buffer containing 2% NP-40. The soluble and the 
insoluble fractions were separated by centrifugation. Indicated proteins were 
detected by western blotting using the corresponding antibodies. The pellets 
represent 4 times the platelet equivalents in the corresponding supernatant fractions. 








Figure 15 Translocation of GIT1-containing complex upon platelet stimulation was 
dependent on Outside-in signaling- and Arf6 activity. Washed platelets (6 × 108 
platelets/mL) were pre-incubated with or without 250 µM RGDS peptide, 10 µM 
MyrArf6 peptide, 10 µM sMyrArf6 peptide as indicated for 3 min in an aggregometer 
then stimulated with 0.1 U/mL thrombin for 3 min. Platelets were lysed in buffer 
containing 2% NP-40. The soluble and the insoluble fractions were separated by 
centrifugation. Indicated proteins were detected by western blotting using 
corresponding antibodies. The pellets represented 15 times the platelet equivalents 





15, pretreatment of washed platelets with myrArf6p, but not myrArf1p, completely 
abolished the translocation, suggesting that Arf6 activity is important. It should also 
be noted that pretreatment with myrArf6p decreased F-actin level in pellet fraction, 
which is consistent with previous observations [414]. There are several possible 
explanations for this effect. One possibility is that myrArf6p affects the activation of 
Rho family members as shown previously [414], which in turn diminish PAK activation, 
GIT1 activation, and complex translocation. Another possibility is that Arf6p affects 
integrin αIIbβ3 activation, and thus abolishes its outside-in signaling and GIT1 
translocation. Indeed, treatment of mryArf6 peptide decreased both active and total 
integrin αIIbβ3 levels on plasma membrane of human platelets in response to 
thrombin (Choi WS, unpublished data). Regardless, GIT1 translocation appears to 
require Arf6 activity, suggesting a positive feedback loop in platelets that regulates 
Arf6. 
GIT1 Phosphorylation Depended on Integrin αIIbβ3 Outside-in Signaling and Arf6 
Activity 
GIT1 phosphorylation is an important mechanism for controlling GIT1 cellular 
activities [450, 451], affecting GIT1’s ArfGAP activity, cellular localization, and its 
interactions with paxillin. Previously, it was shown that tyrosine phosphorylation of 
GIT1 in platelets is affected by different kinases [425]. In Figure 16, GIT1 
phosphorylation is blocked by pretreatment with RGDS peptide, which is consistent 
with previous results [425], suggesting that GIT1 tyrosine phosphorylation requires 
integrin αIIbβ3 outside-in signaling. GIT1 always forms a complex with β-PIX and Hic-
5 (a member of paxillin family present in platelets) regardless of the state of the 
platelets (consistent with previous observations; [425]). Interestingly, integrin β3 
levels in GIT1-containing complexes increased upon platelet activation but this 
increase was not affected by RGDS peptide treatment. These data would suggest that 
the GIT1-containing complex is recruited to the integrins before αIIbβ3 outside-in 
signaling and translocation to detergent-insoluble fraction. GIT1 phosphorylation in 
platelets also requires Arf6 activity since pretreatment of washed platelets with 







Figure 16 GIT1 phosphorylation upon thrombin stimulation depends on outside-in 
signaling and Arf6 activity. Washed platelets (4 × 108 platelets/mL) were pre-
incubated with or without 250 µM RGDS peptide, 10 µM MyrArf6 peptide, 10 µM 
scMyrArf6 peptide as indicated for 3 min in an aggregometer then stimulated with 0.1 
U/mL thrombin for 3 min. Platelets were lysed in buffer containing 2% Triton X-100 
and phosphatase inhibitor cocktail. Co-immunoprecipitation was performed using 
anti-GIT1 antibody. The proteins in the complex were probed using corresponding 




activity is not required for the association of GIT1/β-PIX/Hic-5 complex with integrin 
β3 (Figure 16). Instead, myrArf6p increased the levels of integrin β3 subunit in the 
complex, which might be due to recruitment of GIT1 by Arf6-GTP to integrin. Taken 
together, these data show that GIT1 phosphorylation requires both integrin αIIbβ3 
outside-in signaling and Arf6 activity, but is not required for the association of the 
GIT1-containing complex with the integrin β3 subunit. 
GIT1 Phosphorylation Required the Actin Cytoskeleton 
Since GIT1-containing complexes eventually are translocated to Triton X-100-insoluble 
fractions (which could be F-actin complexes and/or lipid rafts), we wondered if GIT1 
phosphorylation is affected by the actin cytoskeleton. As shown in Figure 17, both 
latrunculin A (latA) and cytochalasin D (cytoD), inhibitors of actin polymerization, 
almost completely inhibit GIT1 phosphorylation without disrupting GIT1-containing 
complex formation or recruitment of GIT1 complexes to integrin β3 subunit. It has 
been known that latA and cytoD do not inhibit platelet aggregation, suggesting that 
actin polymerization is not essential for integrin αIIbβ3 activation [482, 483]; thus 
actin polymerization following integrin αIIbβ3 outside-in signaling appears to be 
important for GIT1 phosphorylation but not its associations with β-PIX and Hic-5 and 
integrin.  
Summary: It appears that, GIT1 complex is dynamically regulated in platelets as shown 
in model (Figure 18). In resting platelets, GIT1 is present in cytoplasm and forms 
complexes with β-PIX and Hic-5. Upon platelet activation, GIT1 complexes are 
recruited to integrins, which is not dependent on integrin αIIbβ3 outside-in signaling, 
Arf6 activity, and actin cytoskeleton network. Following integrin αIIbβ3 outside-in 
signaling, GIT1 gets phosphorylated very likely by Src and/or FAK. This step appears to 
require Arf6 activity and intact actin polymerization. It is proposed that GIT1’s Arf6 
GAP activity is enhanced by phosphorylation, resulting in integrin αIIbβ3-mediated 
loss of Arf6-GTP and leading to the recruitment of whole protein complex to a 
detergent-insoluble fraction.  
Generation of Platelet-specific GIT1 KO Mice 
The work in Figure 14-17 in this chapter was all done with human platelets. To better 








Figure 17 GIT1 phosphorylation upon thrombin stimulation needed intact actin 
polymerization. Washed platelets (4 × 108 platelets/mL) were pre-incubated with or 
without latrunculin A (LatA)  or cytochalasin D (CytoD) as indicated for 3 min in an 
aggregometer then stimulated with 0.1 U/mL thrombin for 3 min. Platelets were lysed 
in buffer containing 2% Triton X-100 and phosphatase inhibitor cocktail. Co-
immunoprecipitation was performed using anti-GIT1 antibody. The proteins in the 










Figure 18 Model of GIT1 regulation in human platelets. In the cytoplasm of resting 
platelets, GIT1 forms a complex with β-PIX and Hic-5, a member of paxillin family. 
Upon platelet activation, GIT1/β-PIX/Hic-5 complex is recruited to integrin cytoplasmic 
tail, which is independent of integrin αIIbβ3 outside-in signaling and Arf6 activity. 
Following integrin αIIbβ3 outside-in signaling by engaging extracellular fibrinogen, 
GIT1 is tyrosine-phosphorylated which requires Arf6 activity and intact actin 
polymerization. Phosphorylated GIT1 mediates second-wave of Arf6-GTP loss and 
activated GEF activity of β-PIX, probably caused by phosphorylation, leads to Rac1 and 
Cdc42 activation and subsequent further platelet activation, like platelet adhesion, 




specific GIT1 KO mice (referred as GIT1 KO). GIT1 KO mice were generated by crossing 
floxed GIT1 mice, a generous gift from Dr. Richard Premont (Duke University, Durham, 
NC), with PF4-Cre mice. Similar to Arf6 KO mice, the target mice for experiments were 
offspring of GIT1flox/flox/Cre- and GIT1flox/flox/Cre+. In initial studies, we had a difficult 
time confirming the loss of GIT1 in platelets by western blotting. One reason was that 
the commercially-available anti-GIT1 antibodies had various efficacies in detecting 
mouse 
GIT1. Only one out of three antibodies that we tried was able to detect the mouse 
GIT1 protein. The second, more important reason for our problems was that the 
expression level of GIT1 protein in mouse platelets is very low. As shown in Figure 19A, 
two sets of mouse platelet lysates were tested. Given the same platelet numbers 
loaded, GIT1 protein levels in mouse platelets were significantly lower compared to 
human samples. With the help from Dr. Premont, it was noticed, in Figure 19B, that 
GIT2 levels were much lower (the big arrow) in human platelets while GIT1 levels were 
much lower in mouse platelets (the small arrow). Therefore, it is likely that GIT2 is the 
dominant isoform in mouse platelets, while GIT1 is the dominant one in human 
platelets. Given our experience with isoforms of secretory components in platelets, 
the dominant one by mass is most often the dominant isoform functionally. 
GIT1 Deficiency in Mouse Platelets Did Not Inhibit the Loss of Arf6-GTP upon Platelet 
Activation 
To test if GIT1 behaves as a critical Arf6GAP protein in platelets, particularly 
downstream of integrin αIIbβ3 outside-in signaling, Arf6-GTP pulldown assays were 
performed using platelets from the GIT1 KO mice and WT controls. As shown in Figure 
20, in WT platelets (black bar), Arf6-GTP levels decreased dramatically upon thrombin 
stimulation as seen in human platelets [417]. Interestingly, GIT1 KO platelets (white 
bar) had a similar pattern of Arf6-GTP loss, suggesting that GIT1 is not an essential GAP 
protein for Arf6 in mouse platelets. 
MyrArf6 Peptide Did Not Block Mouse Platelet Aggregation, for Both WT and Arf6 KO 
Platelets 
From the above observation, it seems that the regulation of Arf6 in mouse platelets is 
probably different from that in human platelets. In fact, a myristoylated Arf6 peptide 








Figure 19 Mouse platelet contained much less GIT1 protein than human. (A-B) Equal 
numbers (1.6 X 107) of washed WT or KO MP and HP were loaded. 100 μg of brain 
tissues or lung tissue were loaded in each sample. For mouse platelet samples, each 
lane represents platelets from a single mouse. Indicated protein were detected by WB. 
Actin was stained by Coomassie blue as loading control. In B, the big arrow points to 








Figure 20 GIT1 depletion in mouse platelets did not affect Arf6-GTP dynamics upon 
thrombin stimulation. (A-B) Washed platelets from WT and KO mice were prepared 
at 5 X 108/ml in HEPES Tyrode’s buffer (pH 7.4) and kept resting or stimulated with 0.1 
U/ml thrombin for the indicated times. The reaction was stopped by addition of 2 X 
GTPases-pulldown lysis buffer containing protease inhibitor cocktail. Arf6-GTP was 
pulled down based on the methods described in method section. The pellets (Arf6-
GTP) and the supernatant (total Arf6) was subjected to western blotting. 
Quantification of the levels of Arf6-GTP and total Arf6l was performed using 
ImageQuantTL. The ratio of Arf6-GTP to total Arf6 was calculated and plotted in bar 






human platelet aggregation (studies here, [414] and the Bristol group), actually did 
not inhibit mouse platelet aggregation. As shown in Figure 21A, myrAf6 peptide 
inhibits human platelet aggregation and ATP release in dose-dependent manner, 
which is consistent with previous observation. However, this peptide did not inhibit 
mouse platelet aggregation or ATP release (Figure 21B). Interestingly, Arf6 deletion in 
mouse platelets had no effect on myrArf6 peptide-pretreated mouse platelet 
aggregation and  
ATP release (Figure 21C). These results suggested that the regulation of Arf6 in mice 
is different from that in humans.  
GIT1 KO Platelets Had no Defect in Fibrinogen Levels or Clot Retraction  
Since Arf6 KO platelets are defective in fibrinogen storage and have enhanced clot 
retraction, the fibrinogen levels and clot retraction were also determined in GIT1 KO 
platelets. As shown in Figure 22, fibrinogen levels were not significantly lower in GIT1 
KO platelets compared to WT. As shown in Figure 23, GIT1 KO platelets had similar 
clot retraction profiles as WT. Taken together, it appears that the GIT1 protein is not 
important in mouse platelets, at least for the functions that were tested.  
Summary: Apparently GIT1 is differentially expressed and used in human platelets 
versus in mouse platelets. This is yet another example in which mouse platelets and 
human platelets differ [484]. In human platelets, cellular localization and 
phosphorylation of GIT1 are regulated by integrin αIIbβ3 outside-in signaling and Arf6 
activity, suggesting that GIT1 could behave as Arf6GAP protein in the second wave 
signaling that was observed by Karim et al. However, it seems that GIT1 is not the 
dominant isoform for Arf6 regulation in mouse platelets since GIT1 depletion had no 
effect on the loss of Arf6-GTP upon platelet activation. This would suggest that GIT2 
may be the critical isoform controlling Arf6 in mouse platelets. This would be 
consistent with expression/function data in platelets where the dominant isoform by 









 Figure 21 MyrArf6 peptide did not block mouse platelet aggregation, for both WT 
and Arf6-/- platelets. Washed platelets were prepared in HEPES-Tyrode’s buffer (pH 
7.4) containing 1 mM Ca2+ and adjusted to 2.5 X 108/ml. Platelet aggregation was 
initiated by addition of 0.1 U/ml thrombin. ATP release was monitored using CHRONO-
LUME reagent (Chrono-log) while platelet aggregation was performed. Data was 
organized using Adobe Photoshop CS5. (A) MyrArf6 peptide inhibits fresh human 
platelet aggregation in dose-dependent manner. Washed Platelets were pre-
incubated with myrArf6 peptide for 3 min in aggregometer in the presence of stirring 
at 37°C. (B) MyrArf6 peptide did not block WT mouse platelet aggregation. Washed 
platelets were pre-incubated with myrArf6 peptide for 1 min in the presence of stirring 
at 37°C. (C, D, E) Arf6 KO platelets have same aggregation profile as WT platelets in 
the response of myrArf6 peptide pretreatment. Wash WT and KO platelets were pre-
incubated with myrArf6 peptide (C, 0 µM, D, 1.5 µM, and E, 2.5 µM) for 1 min in the 










Figure 22 Platelets lacking in GIT1 had normal fibrinogen storage. (A) Comparison of 
endogenous fibrinogen levels among WT, Arf6 KO, and GIT1 KO platelets by western 
blotting. Mouse platelet lysates of WT, Arf6 KO, and GIT1 KO were prepared. 1 X 107 
platelets were loaded each lane and indicated proteins were probed using 
corresponding antibodies. Each lane represents platelets from a single mouse. RabGDI 
was used as a loading control. (B) Quantification of fibrinogen levels in (A) was 








Figure 23 GIT1 deficient in mouse platelets did not affect clot retraction. Washed WT 
and GIT1 KO mouse platelets were prepared in HEPES Tyrode’s buffer (pH 7.4) at 4.0 
X 108/ml. Platelets were supplemented with 1 mM Ca2+ and 0.5 mg/ml fibrinogen. Clot 
retraction was initiated by 0.1 U/ml thrombin. The images were taken at the indicated 





Chapter Five: Arf6 and Endocytosis in Platelet Function 
In the work presented, we have continued to explore Arf6’s role in platelets, using 
biochemical assays and genetic tools: Arf6 KO and GIT1 KO mice. Depletion of Arf6 in 
mouse platelets does not affect the expression levels of other proteins, including 
Arf1/3, Rho family, integrin β3 subunit, and granule marker proteins. Consistent with 
that, no overt morphology defect is noticed on Arf6 KO platelets, though there is a 
slight decrease in platelet size. Interestingly, Arf6 KO platelets are defective in 
fibrinogen storage and uptake, but not in other cargo. Using flow cytometry, no 
detectible defect is observed on the surface levels of integrin αIIbβ3, total or activated. 
Consistently, platelet aggregation and ATP release are not affected in response to 
various agonists. Surprisingly, Arf6 deficiency enhances platelet spreading on 
fibrinogen and clot retraction but these defects do not cause obvious alterations in 
thrombus formation or hemostasis.  
Mechanisms for the Defective Fibrinogen Storage in Arf6 KO Platelets 
It is well-established that platelets and megakaryocytes do not synthesize fibrinogen 
[485] and that fibrinogen that is stored in platelets comes via a receptor-mediated 
endocytosis process with integrin αIIbβ3 as the receptor [29, 486]. This concept is 
confirmed in Figure 2A, where β3 KO platelets contain almost no fibrinogen. Based on 
Arf6 regulation of integrin trafficking [216, 316-319] and fibrinogen trafficking 
pathway in platelets [23], a model of Arf6-involved integrin αIIbβ3 (or fibrinogen) 
endocytic trafficking is proposed (Figure 24). Potentially, Arf6 could play a role in every 
step of endocytic trafficking of integrin αIIbβ3.  
As shown in Figure 1C and 1D, platelet integrin αIIbβ3 levels and plasma fibrinogen 
levels are normal in Arf6 KO mice, suggesting that the fibrinogen storage defect is due 
to defective endocytic-trafficking of fibrinogen in Arf6 KO platelets. According to the 
proposed model in Figure 24, the defective fibrinogen storage (~50% reduction) in 
Arf6 KO platelets could be due to the mechanisms discussed below. 
First, the defective fibrinogen storage in Arf6 KO platelets could be because of less 
fibrinogen been endocytosed. In this scenario, there are two possibilities. One 
possibility is that binding of fibrinogen to integrin αIIbβ3 is less stable in Arf6 KO 
platelets, resulting in less efficient endocytosis of fibrinogen. The other one is that  
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Figure 24 Model for Arf6’s roles in integrin αIIbβ3 trafficking and fibrinogen storage 
in platelets. According to the roles of Arf6 in integrin trafficking in nucleated cells, Arf6 
may play a role in various steps in integrin αIIbβ3 in platelets. There are major two 
endocytic recycling pathways for integrins, Rab4-mediated fast-loop via early 
endosomes and Rab11-mediated slow-loop via endosomal recycling endosomes. Arf6 
may be important in either recycling process or in endocytosis process. Since 
multivesicular bodies (MVBs) are an intermediate stage in the formation of platelet α-
granules, Arf6 may also regulate the integrin transition from early endosome to MVBs, 
resulting the storage of fibrinogen within α-granules. In addition to the endocytosis 
from plasma membrane, endocytosis from open canalicular system (OCS) might also 




depletion of Arf6 causes defective endocytosis of fibrinogen-occupied integrin αIIbβ3. 
There haven’t been any reports that Arf6 regulates integrin activation, thus it is very 
unlikely that Arf6 deletion causes reduction in binding affinity of integrin αIIbβ3 to its 
ligand, fibrinogen. However, it has been shown that endocytic trafficking of active and 
inactive β1 integrins in cancer cells is differentially regulated [316] and that active 
αIIbβ3 integrins in human platelets are preferentially endocytosed [240]. We have 
hypothesized that Arf6 depletion leads to decreased endocytosis of fibrinogen-
occupied integrin αIIbβ3, thus deceased fibrinogen deposit within platelets. However, 
I did not notice any difference on the surface levels of active and inactive integrin 
αIIbβ3 between WT and Arf6 KO platelets (Figure 5), which could be due to the 
insufficient sensitivity of the assay. Regardless of which possibilities, measuring the 
FITC-fibrinogen uptake using washed platelets over the time, particularly the early 
time points, should be able to tell if the endocytosis of fibrinogen-occupied integrin is 
lower or not in Arf6 KO platelets. Moreover, the first possibility (binding affinity) could 
be experimentally test by measuring the surface levels of FITC-fibrinogen over the 
time. 
Second, the defective fibrinogen storage in Arf6 KO platelets could be because that 
endocytosed fibrinogen gets degraded in Arf6 KO platelets rather than be delivered to 
α-granules as in WT platelets, resulting in less fibrinogen deposit within Arf6 KO 
platelets. It has been demonstrated by immunofluorescence microscopy that 
endocytosed fibrinogen is not accumulated in late endosomes or lysosomes in human 
platelets [487], suggesting that degradation in lysosomes is not the major destination 
for endocytosed fibrinogen. If endocytosed fibrinogen gets degraded in Arf6 KO 
platelets, fibrinogen fragments should be shown up by western blotting in low 
molecular weight area in Arf6 KO platelets. If this is the case, it would suggest, 
according to the model, that Arf6 deletion leads to delivering fibrinogen to lysosomes 
for degradation rather than to α-granules or recycling compartments and that Arf6 
may be involved in the transition from MVBs to α-granules, a novel role for Arf6 in 
integrin αIIbβ3 trafficking in platelets. 
Lastly, the defective fibrinogen storage in Arf6 KO platelets could be equally possibly 
due to altered integrin αIIbβ3 recycling. If fibrinogen endocytosis and fibrinogen 
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degradation are not affected in Arf6 KO platelets, one of the possibilities is that 
endocytosed fibrinogen is recycling back to the surface, which is exacerbated by Arf6 
depletion. Arf6 has been suggested to be involved in two recycling pathways of 
integrins (Figure 24), Rab4-mediated fast-recycling pathway and Rab11-mediated 
slow-recycling pathway. In platelets, Arf6 probably is required for slow-recycling 
process and deletion of Arf6 pushes recycling of fibrinogen-occupied integrin αIIbβ3 
to the fast-loop, resulting in less fibrinogen deposited within platelets. It is also 
possible that in platelets Arf6 mediates the trafficking of integrin from endosomes to 
multivesicular bodies and deletion of Arf6 cause decreased accumulation of fibrinogen 
to α-granules.  
Potential Role of Arf6 in Integrin αIIbβ3 Endocytic trafficking in Platelets 
Arf6 regulation of integrin trafficking has been observed in different cells [216, 220] 
and is important for cell migration, neurite outgrowth and tumor metastasis. It 
appears that Arf6 could participate in different routes and different steps of integrin 
trafficking depending on the cell systems, thus it may be difficult to generalize too 
much.  
Our previous studies showed that Arf6-GTP accounts for ~10% of the total Arf6 in 
resting platelets [414, 417]. How do the resting platelets maintain this high amount of 
Arf6-GTP? It was suggested that Arf6 is locked in GTP state by its GEF protein, 
cytohesin2, which is important to sequester the release of dense-granules [353]. 
However, given the fact that Arf6 is indispensable for fibrinogen storage in platelets, 
it is reasonable to speculate that the high ratio of Arf6-GTP/Arf6-GDP in resting 
platelets is consequence of constitutive trafficking of integrin αIIbβ3 between the 
plasma membrane and endocytic compartments.  
In platelets, there is EM evidences suggesting that the trafficking of integrin αIIbβ3 is 
mediated by clathrin-coated vesicles. An integrin αIIbβ3-specific antibody, c7E3 
fab/abciximab, was found to be co-localized with clathrin [233]. Fibrinogen, labeled 
with gold beads, was also shown co-localized with integrin αIIbβ3 [488]. Consistently, 
in primary megakaryocytes and megakaryocytic differentiating human leukemic K562 
cells, uptake of fibrinogen is dependent on integrin αIIbβ3 and clathrin [489].  
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Arf6 could participate in the clathrin-coat assembly for endocytosis of integrin αIIbβ3. 
It is well-known that PI(4,5)P2 is one of the most important lipids regulating clathrin-
mediated endocytosis [292]. Arf6 could induce local accumulation of PI(4,5)P2 by 
activating lipid modification enzymes, such as PLD and PIP5K. Therefore, Arf6 could 
mediate endocytosis of integrin αIIbβ3 by facilitating the recruitment of clathrin coats 
through PI(4,5)P2 (Figure 24). Indeed, Arf6 and PI(4,5)P2 have been shown to play 
roles in clathrin coat recruitment in synaptic vesicle preparations [259] and onto 
liposome [293].  
Arf6 could also be involved in the fission of integrin αIIbβ3-containing vesicles by 
regulating dynamin activity. Arf6 has been shown to regulate the dynamin-dependent 
endocytosis of P2Y receptor in human platelets [54]. Arf6 was proposed to recruit 
NM23-H1, a nucleoside diphosphate kinase which functions as a GTP source for 
dynamin, and thus regulate dynamin-dependent fission of coated vesicles during P2Y 
endocytosis in platelets. Similarly, it has been shown that endocytosis of E-cadherin in 
epithelial cells also requires Arf6-mediated recruitment of NM23-H1, which in turn 
facilitates the dynamin-dependent fission [294].  
It is equally possible that Arf6 is involved in other steps of integrin αIIbβ3 endocytic 
trafficking (Figure 24). For example, Arf6 could regulate the formation of actin 
cytoskeleton or microtubule, which is responsible for moving of the integrin αIIbβ3-
containing vesicles. All these possibilities require further investigation.  
Other Factors may Affect Integrin αIIbβ3 Endocytic Trafficking in Platelets 
Clathrin-mediated endocytosis is a complex, spatiotemporally-coordinated process 
involving many essential factors [490]. Some novel players have been found to be 
specifically involved in integrin αIIbβ3 endocytosis. In human platelets, the Src family 
members, Fyn and Lck, were shown to be co-localized with clathrin-coated vesicles 
[235], suggesting their role in endocytosis. Indeed, the surface levels of integrin αIIb 
subunit, measured by flow cytometry, was slightly higher in fyn-/-lyn-/- platelets 
compared to WT, although it was not statistically significant [236]. These fyn-/-lyn-/- 
platelets were defective in platelet aggregation and ATP release in response to CRP 
(collagen-related peptide) and defective thrombus formation on collagen fibers under 
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flow condition, and had enhanced spreading on fibrinogen [236]. However, it is not 
clear whether these platelets had a fibrinogen storage defect. 
DAB-2 (disabled-2) is another potential regulator of integrin αIIbβ3 endocytosis. It is 
an adapter protein involved in multiple cellular activities. It binds to the NPXY motif of 
integrin β1 through its N-terminal phosphotyrosine binding (PTB) domain [198, 491]. 
Integrin β3 contains two NPXY/NPXY-like motifs in its cytoplasmic tail, which interacts 
with numerous proteins, including DAB2 [492, 493]. DAB2 could potentially mediate 
the trafficking of clathrin-coated vesicle through binding to myosin VI [494]. 
Knockdown of DAB2 in megakaryocytes caused ~50% reduction of fibrinogen uptake 
[489] and DAB2-/- platelets have ~40% reduction in fibrinogen content [237]. These 
platelets are defective in platelet spreading, clot retraction, aggregation in response 
to low concentration of thrombin [237].  
It seems that Integrin αIIbβ3 trafficking occurs not only in resting platelets as discussed 
above but also in activated platelets in response to extracellular stimuli. It was found 
that ADP or TRAP (thrombin receptor activation peptide) stimulation significantly 
increases integrin αIIbβ3 internalization in an actin-dependent manner [240]. Also, 
direct activation of integrin αIIbβ3 with LIBS antibody leads to a ~8-fold increase in the 
extent of integrin αIIbβ3 internalization. These results demonstrate that the endocytic 
magnitude (rate of integrin αIIbβ3 uptake) is different between resting platelets and 
activated platelets, implying that the molecular mechanisms regulating the 
endocytosis of αIIbβ3 might be different in these two states. It seems exceedingly 
possible that there are more regulators to be identified which can affect the 
endocytosis of integrin αIIbβ3.  
In addition, there are many interesting questions that remain to be answered. There 
are two major conformational states of integrin αIIbβ3 in platelets, inactive and 
activated. Is the endocytic trafficking of these two populations regulated in a same 
manner? It has been suggested that the endocytic trafficking of inactive and activated 
β1 integrins is differentially regulated [316]. Therefore, it is possible that αIIbβ3 
trafficking is different depending on which conformation it is in. Also, after the 
clathrin-coated pits are formed, how is the vesicle transported? It has been implicated 
that actin cytoskeleton could be involved since pre-treatment of platelets with 
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Cytochalasin E blocks the internalization of integrin αIIbβ3 in both resting and 
activated platelets. Therefore it would be interesting to look for actin-related proteins, 
like myosin isoforms, which could bind to β3 subunit [495], and, moesin, which was 
reported to regulate trafficking of nascent clathrin-coated vesicles through interaction 
with PI(4,5)P2 [496]. Moreover, it was found that, in CHO cells, the constitutive 
endocytosis of expressed recombinant integrin αIIbβ3 was not affected by deletion of 
the cytoplasmic domain of β3, suggesting a potential role of α subunits in this process 
[202]. However, internalization of fibrinogen-coated particles was affected by this 
deletion, probably due to the compromised affinity of this mutant integrin for 
fibrinogen. It has been well-known from in vivo mutagenesis studies that tyrosine-
containing, sorting motifs are signals for concentration of transmembrane receptors 
into coated pits and are both necessary and sufficient for efficient constitutive 
endocytosis. So, what is the trigger for the constitutive endocytosis of integrin αIIbβ3, 
particularly the inactive conformation? This question becomes more interesting in 
platelets, given the fact that they are not adherent to any surface but are circulating 
in blood as singular entities. 
Potential Hyper-thrombotic Phenotype in Arf6 KO mice 
Flow cytometry (Figure 7) data shows that the surface levels of integrin αIIbβ3 were 
not affected in the Arf6 KO platelets. Given the fact that FACS assay is a static measure 
that reflects the steady state levels of αIIbβ3, it may not report on population of αIIbβ3 
that is rapidly recycling on and off the plasma membrane. It is possible that any change 
in dynamic αIIbβ3 trafficking is too small to be detected by the assay. Further 
experiments are needed to measure small, dynamic changes in integrins on the 
platelet surface. Since Arf6 could affect the endocytic trafficking of integrin αIIbβ3, 
Arf6 depletion was expected to affect platelet functions that are related to integrin 
αIIbβ3. Indeed, Arf6 deficiency enhanced platelet spreading on fibrinogen-coated 
surfaces and promoted platelet clot retraction (Figure 7 and 8). Because Arf6 
depletion did not appear to affect platelet signaling, as shown in Figure 9-11, the 
phenotype observed is probably due to some alteration in the surface availability of 
integrin αIIbβ3. αIIbβ3 could recycle more efficiently in the KO platelets and thus be 
more available to make contacts with fibrinogen. Despite the effects on spreading and 
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clot retraction, deletion of Arf6 did not have an obvious effect on thrombosis or 
hemostasis, in the two arterial thrombosis assays used (Figure 13). Based on the 
spreading and clot retraction phenotype, one might expect that the Arf6 KO mice 
could be hyper-thrombotic. Such a phenotype is more difficult to detect in our 
thrombosis/hemostasis assays. It seems possible that Arf6 KO mice should show 
increased hemostasis and perhaps decreased embolization given the increased 
spreading and clot retraction that their platelets exhibit ex vivo in our assays. Thus it 
will require some additional experimentation and refinement of assay systems to fully 
evaluate the importance of Arf6 function in vivo.  
Arf6 Regulation in Platelets 
Our previous work has shown that Arf6 is regulated by two waves of platelet signaling 
and many well-known signaling components contribute to the process (Karim 2008). 
Since Arf6 has low level of intrinsic GTPase and exchange activities, the switch 
between the two different nucleotide states requires the GAP and GEF proteins. 
Recently, using proteomics, several potential regulators were identified in platelets, 
including ASAP1/2, GIT1/2, ACAP1/2 and cytohesin 2 [497]. This suggests that the 
control of Arf6 in platelets could be complex and that Arf6 could participate in several 
aspects of platelet activation and function. Cytohesin 2, as substrate of protein kinase 
C, has been shown to be functionally relevant to platelet secretion [353]. We 
hypothesized that GIT1 is an important regulator for Arf6 downstream integrin αIIbβ3 
signaling pathway since phosphorylation of GIT1 is regulated by outside-in signaling of 
integrin αIIbβ3 and our data using human platelets is at least consistent with that 
hypothesis. Unfortunately, the mouse system could not be used to probe the role of 
GIT1 in platelets. Arf6GTP levels were not altered in GIT1 KO mouse platelets upon 
thrombin stimulation (Figure 20). Our further analysis showed that GIT1 was not the 
dominant GIT isoform in mice (as it is in humans). Interestingly, GIT2 may be the 
dominant isoform in mouse platelets and thus affect Arf6, downstream of integrin 
αIIbβ3, as GIT1 appears to do in human platelets. More experimentation and 
additional KO mouse strains will be require to resolve this point. 
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Does Fibrinogen Storage-deficiency in Platelets Affect Platelet Function? 
Fibrinogen is synthesized by hepatocytes and released into the plasma. Fibrinogen 
deficiency in mouse and human causes a bleeding disorder [498, 499]. Using 
fibrinogen knockout mice, it has been suggested that fibrinogen may also contribute 
to wound healing [500], metastatic potential, atherogenesis, and affect the intensity 
of inflammation in arthritis. Interestingly, it has been shown that fibrinogen is also 
required for P-selectin expression in platelets [480]. It seems that the engagement of 
the C-terminus of the fibrinogen γ chain and β3 integrin, not through the RGDS binding 
site, plays an important role in this synthesis since platelets from FgγΔ5 (fibrinogen 
lacking the 5 carboxyl-terminal γ chain amino acid) mice had similar deficiency in P-
selectin expression as the one from fibrinogen deficient mice [480]. As shown in Figure 
1, Arf6 KO platelets have normal P-selectin levels compared to control, although there 
is around 50% reduction in fibrinogen content in Arf6 KO platelets. It is possible that 
the engagement of fibrinogen and β3 on platelet surface generates sufficient signal to 
drive de novo synthesis of P-selectin. It is also possible that the internalized fibrinogen 
is needed to maintain P-selectin levels in platelets. Therefore, it would be worthwhile 
to determine whether the P-selectin levels are affected by completely blocking the 
trafficking of β3 integrins. Fibrinogen is one of the major cargo proteins in platelet α-
granules and platelets contain approximately 3% of the total circulating pool of 
fibrinogen [501]. By electron microscopy, it seems that fibrinogen deficient platelets 
have normal morphology and α-granule biogenesis [480], suggesting fibrinogen is not 
required for maintaining platelet morphology. Based on these data, it is not 
completely clear if platelet-derived fibrinogen is functional important for platelets or 
platelet-involved physiological processes.  
The Significance of Platelet Endocytosis 
It has been known for decades that certain cargo molecules in platelet granules are 
internalized and packed in platelets through either receptor-mediated endocytosis 
(e.g. fibrinogen), or pinocytosis (e.g. immunoglobulin, albumin). Autotaxin, also called 
secreted lysophospholipase D, could be another molecule that is internalized by 
platelets since platelets contain undetectable autotaxin mRNA but contain readily 
detectible levels of autotaxin protein [140]. It has been shown that platelet-derived 
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autotaxin binds to β3 integrin, increasing local LPA level and promoting the metastasis 
of breast cancer cells to bone [140]. It has been hypothesized that repacking the cargo 
content into platelets by endocytosis is important for platelets to regain their function 
after transfusion [502, 503]. As shown in Figure 23, inhibition of dynamin-mediated 
endocytosis by dynasore, which inhibits dynamin-mediated fission process, enhances 
platelet clot retraction, mimicking the phenotype of Arf6 KO platelets. Therefore, 
endocytosis is a key mechanism for modulating platelet granule content and thus may 
be important for platelets functions.  
In conclusion, we show for the first time by using mouse model that Arf6 is involved 
in integrin αIIbβ3 trafficking in platelets. Controlling the trafficking of integrin αIIbβ3 
could be an angle to regulate platelet activity and be a therapeutic approach for 
cardiovascular disease. Also, regulating platelet endocytosis, thus the granule content 







ACD                                    Acid citrate dextrose 
ADAP                                   Arf GAP with dual PH domain-containing 
ADHD                                  Attention-deficit hyperactivity disorder 
ADP                                     Adenosine diphosphate 
Arf                                       ADP-ribosylation factor  
Arl                                       Arf-like 
ARNO                                  Arf nucleotide-binding site opener 
ASAP                                   Arf GAP containing SH3, ankyrin repeat and PH domains 
ATP                                     Adenosine triphosphate 
BRAG                                  Brefeldin-resistant Arf GEF 
CHO                                    Chinese hamster ovary 
DAB-2                                 Disabled-2 
DAG                                    Diacylglycerol 
EC                                        Endothelial cells 
ECM                                    Extracellular matrix 
EE                                        Early endosome 
EFA                                     Exchange factor for Arf 
EGF                                     Epithelial growth factor 
EM                                      Electron microscope 
EphA2                                Erythropoietin-producing hepatocellular carcinoma-A2 
ER                                       Endoplasmic reticulum 
ERC                                     Endocytic recycling compartment 
FA                                       Focal adhesion 
FAK                                     Focal adhesion kinase        
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GAP                                    GTPase-activating protein 
GDP                                    Guanosine diphosphate 
GEF                                     Guanine nucleotide exchange factor 
GIT                                      G protein-coupled receptor kinase interacting protein  
GPCR                                  G protein-coupled receptor 
GPI                                      Glycosylphosphatidylinositol 
GPVI                                   Glycoprotein VI 
GSK                                    G protein-coupled receptor kinase 
GT                                      Glanzmann thrombasthenia 
GTP                                    Guanosine triphosphate 
HGF                                    Hepatocyte growth factor 
IP                                        Immunoprecipitation 
IP3                                      Inositol triphosphate 
JIP3                                    JNK-interacting protein 3 
LD                                       Leucine-rich domain 
LPA                                     Lysophosphatidic acid 
MAPK                                 Mitogen-activated protein kinase 
MHC                                   Major histocompatibility complex 
MVB                                   Multivesicular bodies 
NDP                                    Nucleoside diphosphate 
NETs                                   Neutrophil extracellular DNA traps 
NO                                       Nitric Oxide 
OCS                                     Open Canalicular System 
PA                                        Phosphatidic acid 
PAK                                      p21-activated kinase 
PAR                                      Protease-activated receptor 
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PBS                                       Paxillin-binding site 
PDGF                                    Platelet-derived grow factor 
PF4                                       Platelet factor 4 
PGI2                                     Prostaglandin I2 
PGI2                                     Prostacyclin I2 
PH                                        Pleckstrin homology 
PI(4,5)P2                             Phosphatidylinositol 4,5-bisphosphate 
PI3K                                     Phosphoinositide 3-kinase 
PIP5K                                   Phosphatidylinositol 4-phosphate 5 kinase 
PIX                                       PAK interacting exchange factor 
PKC                                      Protein Kinase C 
PKC                                      Protein Kinase C 
PKD                                     Protein kinase D 
PLC                                      Phospholipase C 
PLD                                      Phospholipase D 
PNRC                                   Perinuclear recycling compartment 
PPP                                      Platelet poor plasma 
PRP                                      Platelet rich plasma 
RBC                                      Red blood cells 
RGDS                                   Arginine-glycine-asparagine-serine acid 
Robo4                                 Roundabout homology 4 
S1P                                      Sphingosine-1-phosphate 
SFK                                      Src family kinase 
SH2                                     Src homology 2 
SHD                                    Spa-homology domain 
SNARE                                Soluble N-ethylmaleimide-sensitive fusion protein  
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                                            attachment receptor 
SNPs                                   Single nucleotide polymorphism 
TCIPA                                 Tumor cell induced platelet aggregation 
TF                                       Tissue factor 
TfR                                     Transferrin receptor 
TP                                      Thromboxane A2 receptor 
TRAP                                 Thrombin receptor activation peptide 
TXA2                                 Thromboxane A2 
VAMP8                             Vesicle-associated membrane protein 8 
VEGF                                 Vascular endothelial growth factor 
vWF                                   von Willebrand Factor 
WAVE                                WASP family veroprolin homolog 
WBC                                   White blood cells 
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